<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Adv Med Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Ther Adv Med Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">1560</journal-id><journal-id journal-id-type="pmc-domain">tam</journal-id><journal-id journal-id-type="publisher-id">TAM</journal-id><journal-title-group><journal-title>Therapeutic Advances in Medical Oncology</journal-title></journal-title-group><issn pub-type="ppub">1758-8340</issn><issn pub-type="epub">1758-8359</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11863263</article-id><article-id pub-id-type="pmcid-ver">PMC11863263.1</article-id><article-id pub-id-type="pmcaid">11863263</article-id><article-id pub-id-type="pmcaiid">11863263</article-id><article-id pub-id-type="pmid">40012707</article-id><article-id pub-id-type="doi">10.1177/17588359251321904</article-id><article-id pub-id-type="publisher-id">10.1177_17588359251321904</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>State of the Art and Latest Progress in the Care of Breast Cancer in Young Women</subject><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Risk of second primary cancer in young breast cancer survivors: an important yet overlooked issue</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-6610-1207</contrib-id><name name-style="western"><surname>Liang</surname><given-names initials="X">Xinyi</given-names></name><aff id="aff1-17588359251321904">School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, People&#8217;s Republic of China</aff><aff id="aff2-17588359251321904">Department of Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, People&#8217;s Republic of China</aff><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-1871-4699</contrib-id><name name-style="western"><surname>Qin</surname><given-names initials="Y">Yiwei</given-names></name><aff id="aff3-17588359251321904">Department of Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, People&#8217;s Republic of China</aff><aff id="aff4-17588359251321904">Department of Radiation Oncology, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People&#8217;s Republic of China</aff><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-4037-8569</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="P">Pengwei</given-names></name><aff id="aff5-17588359251321904">Department of Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, People&#8217;s Republic of China</aff><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5283-0741</contrib-id><name name-style="western"><surname>Mo</surname><given-names initials="Y">You</given-names></name><xref rid="fn1-17588359251321904" ref-type="author-notes">*</xref><aff id="aff6-17588359251321904">Department of Cardiovascular Medicine, The First Affiliated Hospital of Shantou University Medical College, Shantou University, No.57, Changping Road, Shantou, Guangdong 515000, People&#8217;s Republic of China</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6762-7997</contrib-id><name name-style="western"><surname>Chen</surname><given-names initials="D">Dawei</given-names></name><xref rid="fn1-17588359251321904" ref-type="author-notes">*</xref><xref rid="corresp2-17588359251321904" ref-type="corresp"/><aff id="aff7-17588359251321904">Department of Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440, Jiyan Road, Huaiyin District, Jinan, Shandong 250000, People&#8217;s Republic of China</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib></contrib-group><author-notes><corresp id="corresp1-17588359251321904"><email>moyou.moyou@163.com</email></corresp><corresp id="corresp2-17588359251321904"><email>dave0505@yeah.net</email></corresp><fn fn-type="equal" id="fn1-17588359251321904"><label>*</label><p>These authors have contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">478142</issue-id><elocation-id>17588359251321904</elocation-id><history><date date-type="received"><day>26</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>4</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>26</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-04 01:25:42.683"><day>04</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s), 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_17588359251321904.pdf"/><abstract><p>Currently, female breast cancer (BC) represents the highest incidence of cancer globally. This trend has raised significant attention regarding breast cancer young women (BCYW). With advancements in treatment technology, BCYW survivors are living longer; however, the risk of developing or succumbing to a second primary cancer (SPC) has greatly increased. In addition, several factors, including age, menstrual cycle, hormonal changes, obesity, pregnancy, and breastfeeding, interact to influence the development of SPC in BCYW and make its treatment more difficult. This study investigates the relationship between BCYW and SPC, focusing on morbidity trends, pathological genomics, recurrence rates, survival times, treatment modalities, and physiological fertility. Most BCYW involve BRCA pathogenic variants or fall under triple-negative and human epidermal growth factor receptor 2-overexpressing subtypes, increasing the risk of SPC. While there are regional variations in survival time following the diagnosis of an SPC, the long-term survival outcomes remain unfavorable. In addition, the choice of treatment for BCYW survivors has a prolonged cumulative toxic effect. The combination of endocrine therapy and chemotherapy is effective in treating BC, but it simultaneously increases the risk of developing an SPC, specifically endometrial cancer. Furthermore, radiotherapy is associated with a heightened risk of contralateral BC and lung cancer. We aim to address existing gaps in the literature and to enhance awareness of the risks associated with SPC in BCYW, thereby offering valuable insights for clinical diagnosis and treatment.</p></abstract><kwd-group><kwd>breast cancer</kwd><kwd>incidence</kwd><kwd>second primary cancer</kwd><kwd>survival</kwd><kwd>therapy</kwd><kwd>young women</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2025</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-17588359251321904"><title>Introduction</title><p>Breast cancer (BC) has surpassed lung cancer to become the most common cancer worldwide and the fourth leading cause of cancer death.<sup>
<xref rid="bibr1-17588359251321904" ref-type="bibr">1</xref>
</sup> Surprisingly, the rise in BC incidence is mostly observed in younger women. Studies show that BC rates in women &lt;40&#8201;years old are steadily increasing,<sup><xref rid="bibr2-17588359251321904" ref-type="bibr">2</xref>,<xref rid="bibr3-17588359251321904" ref-type="bibr">3</xref></sup> with nearly a 2% annual rise among those aged 20&#8211;29, and a 0.2% increase per year for women in their 30&#8201;years old. Fortunately, with the diversification of treatments and the maturity of imaging equipment, the proportion of BC survivors has increased.<sup><xref rid="bibr4-17588359251321904" ref-type="bibr">4</xref>,<xref rid="bibr5-17588359251321904" ref-type="bibr">5</xref></sup> Nevertheless, it is important to recognize that while breast cancer survivors live longer, they face a significantly higher risk of developing or dying from a second cancer.<sup><xref rid="bibr4-17588359251321904" ref-type="bibr">4</xref>,<xref rid="bibr6-17588359251321904" ref-type="bibr">6</xref></sup> In addition, the long-term nature of treatment and complications in younger patients significantly increase the risk of an SPC compared to older women with BC.<sup><xref rid="bibr7-17588359251321904" ref-type="bibr">7</xref>,<xref rid="bibr8-17588359251321904" ref-type="bibr">8</xref></sup></p><p>Based on epidemiological data, approximately 12.30% of breast cancer in young women (BCYW) develop second primary cancer (SPC).<sup>
<xref rid="bibr9-17588359251321904" ref-type="bibr">9</xref>
</sup> Among these, second primary breast cancer (SPBC) accounts for nearly one-third of all SPC, second only to the initial primary breast cancer (PBC).<sup>
<xref rid="bibr10-17588359251321904" ref-type="bibr">10</xref>
</sup> Notably, contralateral breast cancer (CBC) is particularly common.<sup>
<xref rid="bibr11-17588359251321904" ref-type="bibr">11</xref>
</sup> However, women with BC in Europe<sup>
<xref rid="bibr12-17588359251321904" ref-type="bibr">12</xref>
</sup> and the United States<sup>
<xref rid="bibr13-17588359251321904" ref-type="bibr">13</xref>
</sup> face a 20%&#8211;30% higher risk of developing a second non-breast primary cancer. Regarding the location of SPC, research from the Surveillance, Epidemiology, and End Results (SEER) database in the United States in 2019 indicates that the most common site for an SPC in female BC patients is the contralateral breast,<sup>
<xref rid="bibr14-17588359251321904" ref-type="bibr">14</xref>
</sup> followed by uterine cancer,<sup>
<xref rid="bibr15-17588359251321904" ref-type="bibr">15</xref>
</sup> ovarian cancer,<sup>
<xref rid="bibr16-17588359251321904" ref-type="bibr">16</xref>
</sup> lung cancer,<sup>
<xref rid="bibr17-17588359251321904" ref-type="bibr">17</xref>
</sup> stomach cancer, colorectal cancer,<sup>
<xref rid="bibr18-17588359251321904" ref-type="bibr">18</xref>
</sup> thyroid cancer,<sup><xref rid="bibr15-17588359251321904" ref-type="bibr">15</xref>,<xref rid="bibr19-17588359251321904" ref-type="bibr">19</xref></sup> and acute myeloid leukemia.<sup>
<xref rid="bibr20-17588359251321904" ref-type="bibr">20</xref>
</sup> It is evident that with the long-term effects of BC treatment, the risk of developing SPC increases,<sup>
<xref rid="bibr21-17588359251321904" ref-type="bibr">21</xref>
</sup> with contralateral second primary breast cancer being more common.</p><p>The rate of young-onset BC has been rising each year, along with the risk of SPC. Studies suggest this is linked to tumor size, germline pathogenic variants (PVs),<sup>
<xref rid="bibr22-17588359251321904" ref-type="bibr">22</xref>
</sup> and family history.<sup>
<xref rid="bibr23-17588359251321904" ref-type="bibr">23</xref>
</sup> Despite these risk factors, there is no systematic study describing the biological behavior and treatment-related risks of BCYW and SPC. This paper aims to comprehensively elaborate the incidence, pathological molecular subtypes, survival, susceptibility genes, treatment, and reproductive outcomes in BCYW with SPC, addressing gaps in current research. It highlights the importance of focusing on SPC in BCYW to provide valuable guidance for clinical diagnosis and treatment.</p></sec><sec id="section2-17588359251321904"><title>Increasing incidence trends of BCYW and SPC</title><p>Globally, the incidence of BCYW is on the rise,<sup>
<xref rid="bibr24-17588359251321904" ref-type="bibr">24</xref>
</sup> with approximately 25% of cases occurring in women under the age of 50.<sup>
<xref rid="bibr25-17588359251321904" ref-type="bibr">25</xref>
</sup> Experts generally agree that BCYW should be defined as occurring in women under 40 based on clinical and biological characteristics.<sup>
<xref rid="bibr26-17588359251321904" ref-type="bibr">26</xref>
</sup> A U.S. study of 134,518 women under 40 with BC across 42 states found the highest average annual percentage change (AAPC&#8201;=&#8201;1.00%) in Asian Pacific American women, followed by non-Hispanic white women (AAPC&#8201;=&#8201;0.50%) and non-Hispanic black women (AAPC&#8201;=&#8201;0.30%; <xref rid="table1-17588359251321904" ref-type="table">Table 1</xref>).<sup>
<xref rid="bibr27-17588359251321904" ref-type="bibr">27</xref>
</sup> In a 20-year retrospective study of BCYW in China, the age-standardized percentage (ASP) of cases under 35 rose from 4% in 2000 to 5.9% in 2017, with incidence increasing by about 2% annually.<sup>
<xref rid="bibr28-17588359251321904" ref-type="bibr">28</xref>
</sup> In France, the highest increase in incidence was seen in younger BC patients, with an AAPC of 2.10%.<sup>
<xref rid="bibr29-17588359251321904" ref-type="bibr">29</xref>
</sup> In Iran, the rise in BC incidence primarily stems from the younger age group. The AAPC in the 20&#8211;29 age group (AAPC&#8201;=&#8201;10.0) is twice as high as that in the 30&#8211;39 age group (AAPC&#8201;=&#8201;5.10).<sup><xref rid="bibr30-17588359251321904" ref-type="bibr">30</xref>,<xref rid="bibr31-17588359251321904" ref-type="bibr">31</xref></sup> In a study on young BC in West Africa (Gambia), the AAPC for women aged 50 and older was 1.30%, while the AAPC for women under 50 reached 7.6%. It is clear that the annual growth rate of BC incidence is higher in women aged 50 and under compared to those over 50.<sup>
<xref rid="bibr32-17588359251321904" ref-type="bibr">32</xref>
</sup> Overall, the average annual increase in BCYW incidence is at least 2% (<xref rid="fig1-17588359251321904" ref-type="fig">Figure 1</xref>), with the highest incidence observed in the 30&#8211;35 age group. Young BC is the primary concern for women under 40, and the issues of recurrence and the risk of SPC also pose urgent challenges.</p><table-wrap position="float" id="table1-17588359251321904" orientation="portrait"><label>Table 1.</label><caption><p>Summary of partial characteristics of breast cancer in young women.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17588359251321904-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">Origin of cancer registry</th><th align="left" rowspan="1" colspan="1">Status and characteristics in BCYW</th><th align="left" rowspan="1" colspan="1">Date</th><th align="left" rowspan="1" colspan="1">Number of patients</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Incidence</td><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">AAPC&#8201;=&#8201;1.0% (APA women), AAPC&#8201;=&#8201;0.5% (NHW women), AAPC&#8201;=&#8201;0.3% (NHB women)</td><td rowspan="1" colspan="1">2001&#8211;2015</td><td rowspan="1" colspan="1">134,518</td><td rowspan="1" colspan="1">27</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">China</td><td rowspan="1" colspan="1">ASP increased from 4.0% to 5.9% from 2000 to 2017, with an annual increase of 2.0%</td><td rowspan="1" colspan="1">2000&#8211;2017</td><td rowspan="1" colspan="1">1,308</td><td rowspan="1" colspan="1">28</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">France</td><td rowspan="1" colspan="1">AAPC&#8201;=&#8201;2.1%</td><td rowspan="1" colspan="1">1999&#8211;2018</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">29</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Iran</td><td rowspan="1" colspan="1">AAPC&#8201;=&#8201;10.0% (20&#8211;29 age group), AAPC&#8201;=&#8201;5.1% (30&#8211;39 age group)</td><td rowspan="1" colspan="1">2004&#8211;2013</td><td rowspan="1" colspan="1">2,106</td><td rowspan="1" colspan="1">30</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Africa</td><td rowspan="1" colspan="1">AAPC&#8201;=&#8201;7.6% (in BCYW), AAPC&#8201;=&#8201;1.3% (in older women)</td><td rowspan="1" colspan="1">1990&#8211;2014</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">32</td></tr><tr><td rowspan="1" colspan="1">Recurrence or metastasis</td><td rowspan="1" colspan="1">Multiple Countries</td><td rowspan="1" colspan="1">MCRR&#8201;=&#8201;3.1% (in 5&#8211;10&#8201;years), MCRR&#8201;=&#8201;7.9% (in 10&#8201;years)</td><td rowspan="1" colspan="1">1980&#8211;2009</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">33</td></tr><tr><td rowspan="1" colspan="1">Molecular subtype</td><td rowspan="1" colspan="1">China</td><td rowspan="1" colspan="1">TNBC&#8201;=&#8201;18.1%, HER2/neu overexpression&#8201;=&#8201;8.0%</td><td rowspan="1" colspan="1">2004&#8211;2014</td><td rowspan="1" colspan="1">24,474</td><td rowspan="1" colspan="1">34</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Mexico</td><td rowspan="1" colspan="1">TNBC&#8201;=&#8201;37.1%, Luminal A&#8201;=&#8201;37.1%, HER2&#8201;=&#8201;13.5%, Luminal B&#8201;=&#8201;12.2%</td><td rowspan="1" colspan="1">2012&#8211;2017</td><td rowspan="1" colspan="1">282</td><td rowspan="1" colspan="1">35</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Switzerland</td><td rowspan="1" colspan="1">TNBC&#8201;=&#8201;10.4%, Luminal A&#8201;=&#8201;32.8%, Luminal B&#8201;=&#8201;37.5%</td><td rowspan="1" colspan="1">1970&#8211;2012</td><td rowspan="1" colspan="1">1,586</td><td rowspan="1" colspan="1">36</td></tr><tr><td rowspan="1" colspan="1">Survival time</td><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">5-year OS&#8201;=&#8201;90.0%, BCSS&#8201;=&#8201;91.2%, HR+ HER2&#8722; BCSS&#8201;=&#8201;92.9%, TNBC BCSS&#8201;=&#8201;81.7%</td><td rowspan="1" colspan="1">2010&#8211;2018</td><td rowspan="1" colspan="1">18,400</td><td rowspan="1" colspan="1">37</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">China</td><td rowspan="1" colspan="1">5-year OS&#8201;=&#8201;93.9%, BCSS&#8201;=&#8201;94.2%, HR+ HER2&#8722; BCSS&#8201;=&#8201;96.3%, TNBC BCSS&#8201;=&#8201;88.0%</td><td rowspan="1" colspan="1">2008&#8211;2019</td><td rowspan="1" colspan="1">2,459</td><td rowspan="1" colspan="1">37</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Switzerland</td><td rowspan="1" colspan="1">10-year OS&#8201;=&#8201;68.0%, 10-year DFS&#8201;=&#8201;68.0%, 20-year DFS&#8201;=&#8201;60.0%</td><td rowspan="1" colspan="1">1970&#8211;2012</td><td rowspan="1" colspan="1">1,586</td><td rowspan="1" colspan="1">36</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">10-year OS&#8201;=&#8201;73.0%, 10-year DFS&#8201;=&#8201;48.0%</td><td rowspan="1" colspan="1">1990&#8211;2010</td><td rowspan="1" colspan="1">529</td><td rowspan="1" colspan="1">38</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Multiple Countries</td><td rowspan="1" colspan="1">8-year DFS (HER2&#8722;) Luminal B&#8201;=&#8201;69.0%, Luminal A&#8201;=&#8201;62.0%, TNBC&#8201;=&#8201;63.0%</td><td rowspan="1" colspan="1">2000&#8211;2020</td><td rowspan="1" colspan="1">3,547</td><td rowspan="1" colspan="1">39</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Multiple Countries</td><td rowspan="1" colspan="1">8-year DFS HR+&#8201;=&#8201;65.8%, HR&#8722;&#8201;=&#8201;63.4%<break/>8-year OS HR+&#8201;=&#8201;88.1%, HR&#8722;&#8201;=&#8201;87.1%</td><td rowspan="1" colspan="1">2000&#8211;2020</td><td rowspan="1" colspan="1">4,718</td><td rowspan="1" colspan="1">40</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">8-year DSF Luminal B&#8201;=&#8201;69.7%, Luminal A&#8201;=&#8201;60.8%, TNBC&#8201;=&#8201;63.5%, HER2+&#8201;=&#8201;65.5%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">8-year OS Luminal B&#8201;=&#8201;90.1%, Luminal A&#8201;=&#8201;87.8%, TNBC&#8201;=&#8201;87.0%, HER2+&#8201;=&#8201;87.2%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Susceptibility gene</td><td rowspan="1" colspan="1">UK</td><td rowspan="1" colspan="1">BRCA 12.0% BCYW (&lt;40&#8201;years)</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">2,733</td><td rowspan="1" colspan="1">41</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">BRCA 9.4% BCYW (&#10877;35&#8201;years)</td><td rowspan="1" colspan="1">1990&#8211;1992</td><td rowspan="1" colspan="1">203</td><td rowspan="1" colspan="1">42</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">SOFT Clinical Trial</td><td rowspan="1" colspan="1">Higher GATA3 PVs 19.0% and copy number 47.0%, lower PIK3CA PVs 32.0%, CDH1 PVs 3.0%, MAP3K1 PVs 7.0%</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">1,276</td><td rowspan="1" colspan="1">43</td></tr><tr><td rowspan="1" colspan="1">Therapy</td><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">CRRS increased from 10.0% in 2004 to 33.0% in 2012</td><td rowspan="1" colspan="1">2004&#8211;2012</td><td rowspan="1" colspan="1">1,224,947</td><td rowspan="1" colspan="1">44</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Multiple Countries</td><td rowspan="1" colspan="1">OFS or ovarian elimination reduces 15-year recurrence risk, BCSS, and OS</td><td rowspan="1" colspan="1">1995&#8211;2000</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">45</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-17588359251321904"><p>AAPC, average annual percentage change; APA women, Asian Pacific American women; ASP, annual standard percentage; BCSS, breast cancer-specific survival; BCYW, breast cancer in young women; CRR, cumulative relapse rate; CRRS, contralateral risk reduction surgery; DFS, disease-free survival; HER2&#8722;, human epidermal growth factor receptor 2 negative; HER2+, human epidermal growth factor receptor 2 positive; HR, hazard ratio; HR+, hormone receptor-positive; HR&#8722;, hormone receptor-negative; HR+ HER2&#8722;, hormone receptor-positive and human epidermal growth factor receptor 2 negative; MCRR, median cumulative recurrence rate; NHB women, non-Hispanic Blacks women; NHW women, non-Hispanic White women; OFS, ovarian function suppression; OS, overall survival; PVs, pathogenic variants; TNBC, triple-negative breast cancer.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="fig1-17588359251321904" orientation="portrait"><label>Figure 1.</label><caption><p>High-risk factors for breast cancer in young women. Analysis and summary of high-risk factors in the incidence, molecular subtype, survival time, therapy, susceptibility genes, and physiological fertility in young breast cancer patients.</p><p>Source: Some elements in the figure (such as characters and icons) were created using BioRender.</p><p>BCSS, breast cancer-specific survival; HER2+, human epidermal growth factor receptor 2; HR&#8211;, hormone receptor-negative; OS, overall survival; TNBC, triple-negative breast cancer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17588359251321904-fig1.jpg"/></fig><p>According to research, women younger than 40&#8201;years of age have a higher risk of local recurrence and distant metastasis than older women.<sup>
<xref rid="bibr46-17588359251321904" ref-type="bibr">46</xref>
</sup> In a review of recurrence risk in BCYW, the median cumulative recurrence rate (MCRR) over 5&#8211;10&#8201;years of ipsilateral BC was 3.10%, and the 10-year MCRR was 7.90%.<sup>
<xref rid="bibr33-17588359251321904" ref-type="bibr">33</xref>
</sup> Obviously, young BC has a higher risk of recurrence within 10&#8201;years; however, the occurrence of an SPC is often overlooked. In the United States, the 5-year cumulative incidence (CI) of an SPC in BC is 0.89% (<xref rid="table2-17588359251321904" ref-type="table">Table 2</xref>).<sup>
<xref rid="bibr47-17588359251321904" ref-type="bibr">47</xref>
</sup> Another study of BC patients found racial and ethnic differences in the risk of developing an SPC. Asian American, Native Hawaiian, or other Pacific Islander (standardized incidence ratio, SIR&#8201;=&#8201;1.49), Black (SIR&#8201;=&#8201;1.41), and Latino women (SIR&#8201;=&#8201;1.45) had a 40%&#8211;49% higher risk of developing a second cancer, while white women had a lower but still 9% higher risk compared to the general population (SIR&#8201;=&#8201;1.09).<sup>
<xref rid="bibr48-17588359251321904" ref-type="bibr">48</xref>
</sup> SIR is a relative index obtained by comparing the actual incidence rate of a specific population with the expected incidence rate. The expected incidence rate is calculated based on the incidence rate of a standard population. The SIR can help assess whether the incidence of a specific population is higher or lower than that of the standard population.<sup><xref rid="bibr48-17588359251321904" ref-type="bibr">48</xref>,<xref rid="bibr49-17588359251321904" ref-type="bibr">49</xref></sup> In a study of 53,783 female BC patients in Taiwan, the overall 5-year SIR of second primary non-breast cancer (SPNBC) was 1.09, with no increase in patients over 50 but a significant rise in those under 50 (SIR&#8201;=&#8201;1.43).<sup>
<xref rid="bibr50-17588359251321904" ref-type="bibr">50</xref>
</sup> Studies in northern Portugal found that patients with a first PBC had an SIR of 1.36 for all types of SPC and an SIR of 9.72 for SPC that occurred simultaneously, meaning those diagnosed within a short period (usually within 2&#8201;months) after the first PBC diagnosis.<sup>
<xref rid="bibr51-17588359251321904" ref-type="bibr">51</xref>
</sup> The SIR of SNBC within 10&#8201;years in Korean breast cancer patients was 5.78.<sup>
<xref rid="bibr52-17588359251321904" ref-type="bibr">52</xref>
</sup> Studies from the four regions mentioned above revealed that the 5-year SIR of SPC in BCYW ranged from 1.36 to 1.50 (<xref rid="fig2-17588359251321904" ref-type="fig">Figure 2</xref>). The occurrence of SPC in BCYW was more prominent in the United States and South Korea. Several studies analyzed the interval times between the first BC and SPC; a Canadian study (2006&#8211;2016) found a median interval of 7.3&#8201;years.<sup>
<xref rid="bibr53-17588359251321904" ref-type="bibr">53</xref>
</sup> Similar findings were observed in the Korean study, young BC patients developed a SPC within 7.61&#8201;years of their primary BC diagnosis.<sup>
<xref rid="bibr52-17588359251321904" ref-type="bibr">52</xref>
</sup> In a U.S. cohort of 3223 women with BC, 719 SPC cases were detected over an average follow-up of 11.2&#8201;years. This indicates that most SPCs were diagnosed within 10&#8201;years.</p><table-wrap position="float" id="table2-17588359251321904" orientation="portrait"><label>Table 2.</label><caption><p>Summary of partial characteristics of breast cancer in second primary cancer.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17588359251321904-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">Origin of cancer registry</th><th align="left" rowspan="1" colspan="1">Status and characteristics in SPC</th><th align="left" rowspan="1" colspan="1">Date</th><th align="left" rowspan="1" colspan="1">Number of patients</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Incidence</td><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">CIR&#8201;=&#8201;0.89% (within 5&#8201;years)</td><td rowspan="1" colspan="1">1990&#8211;2019</td><td rowspan="1" colspan="1">416,566</td><td rowspan="1" colspan="1">47</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">SIR&#8201;=&#8201;1.49 (AANHPI women), SIR&#8201;=&#8201;1.41 (Black women), SIR&#8201;=&#8201;1.45 (Latina women),<break/>SIR&#8201;=&#8201;1.09 (White women)</td><td rowspan="1" colspan="1">2000&#8211;2017</td><td rowspan="1" colspan="1">717,335</td><td rowspan="1" colspan="1">48</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">China</td><td rowspan="1" colspan="1">SPNBC SIR&#8201;=&#8201;1.09 (within 5&#8201;years)</td><td rowspan="1" colspan="1">1979&#8211;2003</td><td rowspan="1" colspan="1">53,783</td><td rowspan="1" colspan="1">50</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Portugal</td><td rowspan="1" colspan="1">SIR&#8201;=&#8201;1.36</td><td rowspan="1" colspan="1">2000&#8211;2010</td><td rowspan="1" colspan="1">15,981</td><td rowspan="1" colspan="1">51</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Korea</td><td rowspan="1" colspan="1">SPNBC SIR&#8201;=&#8201;5.78 (within 10&#8201;years)</td><td rowspan="1" colspan="1">2003&#8211;2008</td><td rowspan="1" colspan="1">52,506</td><td rowspan="1" colspan="1">52</td></tr><tr><td rowspan="1" colspan="1">Molecular subtype</td><td rowspan="1" colspan="1">Korea</td><td rowspan="1" colspan="1">TNBC 10-year CI&#8201;=&#8201;12.4%, HER2/neu overexpression 10-year CI&#8201;=&#8201;6.1%, HR+ 10-year CI&#8201;=&#8201;4.8%</td><td rowspan="1" colspan="1">1999&#8211;2013</td><td rowspan="1" colspan="1">16,251</td><td rowspan="1" colspan="1">54</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">TNBC with SPC (HR&#8201;=&#8201;1.77, 95% CI, 1.46&#8211;2.15), HER2/neu overexpression with SPC<break/> (HR&#8201;=&#8201;1.37, 95% CI, 0.99&#8211;1.89)</td><td rowspan="1" colspan="1">1990&#8211;2010</td><td rowspan="1" colspan="1">250,764</td><td rowspan="1" colspan="1">55</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">UK</td><td rowspan="1" colspan="1">HER2+ with SPC (HR&#8201;=&#8201;0.93, 95% CI, 0.89&#8211;0.97)</td><td rowspan="1" colspan="1">1995&#8211;2019</td><td rowspan="1" colspan="1">281,403</td><td rowspan="1" colspan="1">56</td></tr><tr><td rowspan="1" colspan="1">Survival time</td><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">20-year OS&#8201;=&#8201;49.21%, 15-year OS&#8201;=&#8201;66.16%,<break/>10-year OS&#8201;=&#8201;85.77%</td><td rowspan="1" colspan="1">1990&#8211;2010</td><td rowspan="1" colspan="1">250,764</td><td rowspan="1" colspan="1">55</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">China (Shanghai)</td><td rowspan="1" colspan="1">15-year OS&#8201;=&#8201;56.44%, 10-year OS&#8201;=&#8201;64.42%,<break/>5-year OS&#8201;=&#8201;88.34%</td><td rowspan="1" colspan="1">2002&#8211;2015</td><td rowspan="1" colspan="1">163</td><td rowspan="1" colspan="1">57</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">China (Taiwan)</td><td rowspan="1" colspan="1">15-year OS&#8201;=&#8201;23.00%, 10-year OS&#8201;=&#8201;30.00%,<break/>5-year OS&#8201;=&#8201;40.00%, 1-year OS&#8201;=&#8201;71.00%</td><td rowspan="1" colspan="1">1979&#8211;2003</td><td rowspan="1" colspan="1">53,783</td><td rowspan="1" colspan="1">50</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Korea</td><td rowspan="1" colspan="1">5-year OS&#8201;=&#8201;62.28%</td><td rowspan="1" colspan="1">2003&#8211;2008</td><td rowspan="1" colspan="1">52,506</td><td rowspan="1" colspan="1">52</td></tr><tr><td rowspan="1" colspan="1">Susceptibility gene</td><td rowspan="1" colspan="1">Multiple countries</td><td rowspan="1" colspan="1">5-year CR BRCA 1&#8201;=&#8201;15.00%, BRCA2&#8201;=&#8201;9.00%, 10-year CR BRCA1&#8201;=&#8201;27.00%, BRCA2&#8201;=&#8201;19.00%</td><td rowspan="1" colspan="1">1975&#8211;2011</td><td rowspan="1" colspan="1">4,693</td><td rowspan="1" colspan="1">58</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">China</td><td rowspan="1" colspan="1">10-year CR BRCA1&#8201;=&#8201;15.50%, BRCA2&#8201;=&#8201;17.50%,<break/>10-year CR BRCA1&#8201;=&#8201;21.50% (&#10877;&#8201;40&#8201;years)</td><td rowspan="1" colspan="1">2003&#8211;2015</td><td rowspan="1" colspan="1">9,401</td><td rowspan="1" colspan="1">59</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">Germ line PVs carrier 5-year CR&#8201;=&#8201;5.50%,<break/>10-year CR&#8201;=&#8201;8.90%</td><td rowspan="1" colspan="1">2006&#8211;2015</td><td rowspan="1" colspan="1">1,279</td><td rowspan="1" colspan="1">60</td></tr><tr><td rowspan="1" colspan="1">Therapy</td><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">10-year CRRS with SPC&#8201;=&#8201;0.93%,<break/> UM with SPC&#8201;=&#8201;4.44%<break/>15-year CRRS with SPC&#8201;=&#8201;1.15%,<break/> UM with SPC&#8201;=&#8201;7.77%</td><td rowspan="1" colspan="1">1998&#8211;2013</td><td rowspan="1" colspan="1">180,068</td><td rowspan="1" colspan="1">61</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">UK</td><td rowspan="1" colspan="1">Hormonotherapy SIR&#8201;=&#8201;2.30,<break/>without Hormonotherapy SIR&#8201;=&#8201;1.95</td><td rowspan="1" colspan="1">1995&#8211;2019</td><td rowspan="1" colspan="1">281,403</td><td rowspan="1" colspan="1">56</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">Radiotherapy with higher SPC (SHR&#8201;=&#8201;1.16), chemotherapy with lower SPC (SHR&#8201;=&#8201;0.88)</td><td rowspan="1" colspan="1">2000&#8211;2015</td><td rowspan="1" colspan="1">9,247</td><td rowspan="1" colspan="1">62</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Multiple countries</td><td rowspan="1" colspan="1">Radiotherapy with lung cancer (SHR&#8201;=&#8201;1.11), with breast cancer (SHR&#8201;=&#8201;1.39), with AML (SHR&#8201;=&#8201;1.30)</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">63&#8211;66</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Multiple countries</td><td rowspan="1" colspan="1">Radiotherapy ATM with rare missense variant&#8201;=&#8201;16.00% (10-year CR)</td><td rowspan="1" colspan="1">1985&#8211;2000</td><td rowspan="1" colspan="1">2,107</td><td rowspan="1" colspan="1">67</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">Chemotherapy with lung cancer (SHR&#8201;=&#8201;0.90),<break/>with breast cancer (SHR&#8201;=&#8201;0.89)</td><td rowspan="1" colspan="1">2001&#8211;2014</td><td rowspan="1" colspan="1">442,234</td><td rowspan="1" colspan="1">68</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn2-17588359251321904"><p>CIR, cumulative incidence rate; CR, cumulative risk; CRRS, contralateral risk reduction surgery; HR, hazard ratio; OS, overall survival; PVs, pathogenic variants; SHR, sub-hazard ratio; SIR, standardized incidence rate; SPC, second primary cancer; SPNBC, second primary non-breast cancer; TNBC, triple-negative breast cancer; UM, unilateral mastectomy.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="fig2-17588359251321904" orientation="portrait"><label>Figure 2.</label><caption><p>Risk factors and solutions for the development of a second primary cancer. Summary of the highest risk factors of young breast cancer survivors and preventive measures, based on six areas, incidence, molecular subtype, survival time, therapy, susceptibility gene, and physiological fertility.</p><p>Source: Some elements in the figure (such as characters) were created using BioRender.</p><p>BC, breast cancer; BM, bilateral mastectomy; CT, chemotherapy; ET, endocrine therapy; HER2+, human epidermal growth factor receptor 2; HR&#8211;, hormone receptor-negative; PVs, pathogenic variants; RT, radiotherapy; SIR, standardized incidence ratio; SPC, second primary cancer; TNBC, triple-negative breast cancer; UM, unilateral mastectomy.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17588359251321904-fig2.jpg"/></fig><p>In summary, the incidence of young BC is high, and the risk of recurrence within 10&#8201;years is also elevated. While there is no significant variation in the 5-year SIR of SPC among BCYW across different countries, all rates are increasing. Most SPCs occur within 10&#8201;years after the first diagnosis.</p></sec><sec id="section3-17588359251321904"><title>Molecular subtypes impact BCYW and SPC</title><p>Across various studies, 34%&#8211;54% of women diagnosed with BCYW have been found to have TNBC.<sup>
<xref rid="bibr40-17588359251321904" ref-type="bibr">40</xref>
</sup> In a study, very young BC patients exhibited a higher incidence of TNBC subtypes (18.10% vs a mean of 8.60%), and an increased rate of HER2 overexpression (8.00% vs a mean of 6.40%).<sup>
<xref rid="bibr34-17588359251321904" ref-type="bibr">34</xref>
</sup> Furthermore, a study on molecular subtyping of BCYW in Mexico found that the incidence of TNBC and Luminal A was the highest, both at 37.14%. By contrast, the incidence of the HER2 subtype was lower at 13.47%, and Luminal B occurred at a rate of 12.24%.<sup>
<xref rid="bibr35-17588359251321904" ref-type="bibr">35</xref>
</sup> Nonetheless, a study in Switzerland found that most patients were diagnosed with the molecular subtypes Luminal A and Luminal B, at 32.8% and 37.5% respectively. By contrast, TNBC comprised only 10.40% of tumors, making it the least prevalent subtype.<sup>
<xref rid="bibr36-17588359251321904" ref-type="bibr">36</xref>
</sup> The above studies fully confirmed that the molecular subtypes of BCYW are mostly TNBC or HER2 overexpression types, and the other types also exist but account for a relatively small and uncommon proportion.</p><p>BCYW are more likely to develop SPC because their molecular subtypes are often TNBC, HER2 overexpression, or HR&#8211;. For young patients with TNBC, a study conducted in Korea revealed that this subtype was linked to the highest incidence of CBC. Specifically, the 10-year CI of CBC was 12.40% in the TNBC group and the 10-year CI of CBC associated with HER2 overexpression was 6.10%. The incidence of HR+ BC was notably lower than that of the first two molecular subtypes, with rates of 4.80% and 2.70%, respectively (<italic toggle="yes">p</italic>&#8201;=&#8201;0.002).<sup>
<xref rid="bibr54-17588359251321904" ref-type="bibr">54</xref>
</sup> Similarly, multiple studies in the United States have found that TNBC significantly increased the risk of CBC (HR&#8201;=&#8201;1.77, 95% CI&#8201;=&#8201;1.46&#8211;2.15).<sup><xref rid="bibr55-17588359251321904" ref-type="bibr">55</xref>,<xref rid="bibr69-17588359251321904" ref-type="bibr">69</xref></sup> HER2 overexpression in the first BC was strongly associated with an increased risk of CBC (HR&#8201;=&#8201;1.37, 95% CI&#8201;=&#8201;0.99&#8211;1.89). This finding suggests that HER2 overexpression and TNBC in young women in the United States carry a high risk of developing an SPBC.<sup>
<xref rid="bibr55-17588359251321904" ref-type="bibr">55</xref>
</sup> In the British HER2-positive study, the results were inconsistent. Young patients with HER2+ BC exhibited a 7% lower risk of developing an SPNBC (HR&#8201;=&#8201;0.93, 95% CI&#8201;=&#8201;0.89&#8211;0.97).<sup>
<xref rid="bibr56-17588359251321904" ref-type="bibr">56</xref>
</sup> In summary, the molecular subtypes TNBC, HER2 overexpression, and HR-negative are closely associated with the occurrence of SPC.</p></sec><sec id="section4-17588359251321904"><title>Poor survival of SPCs in long-term survivors of BCYW</title><sec id="section5-17588359251321904"><title>Survival time of BCYW</title><p>The survival time of BCYW and the prognosis of the SPC have become the focus of attention. The high tumor burden, advanced stage, and greater aggressiveness in BCYW increase the risk of SPC and impact patient survival.<sup>
<xref rid="bibr38-17588359251321904" ref-type="bibr">38</xref>
</sup> Two studies compared survival outcomes between young Chinese women and white American women with BC (<xref rid="fig1-17588359251321904" ref-type="fig">Figure 1</xref>). The results showed that the white American women had lower 5-year overall survival (OS; 90.00% vs 93.90%, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and breast cancer-specific survival (BCSS; 91.20% vs 94.20%, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).<sup>
<xref rid="bibr37-17588359251321904" ref-type="bibr">37</xref>
</sup> Similarly, it was observed that the 5-year BCSS in young Chinese women was significantly higher than in young white women for both HR+/HER2-and TNBC (96.30% vs 92.90%, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; 88.00% vs 81.70%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.006).<sup>
<xref rid="bibr37-17588359251321904" ref-type="bibr">37</xref>
</sup> However, a study conducted in Switzerland reported longer survival times. The 10-year OS for young BC patients was approximately 68%, with a 10-year disease-free survival (DFS) rate of 68% (95% CI&#8201;=&#8201;0.66&#8211;0.71). After 20&#8201;years, the DFS rate dropped to 60% (95% CI&#8201;=&#8201;0.57&#8211;0.63).<sup>
<xref rid="bibr36-17588359251321904" ref-type="bibr">36</xref>
</sup> In a similar study, it was found that the 10-year OS rate for BC patients aged 35 and younger was 73%, while the 10-year DFS rate for this age group was 48%.<sup>
<xref rid="bibr38-17588359251321904" ref-type="bibr">38</xref>
</sup> For BCYW, the 10-year OS is about 70%, and young Chinese women have better survival benefits than American women in both OS and BCSS.</p><p>Further molecular subtype studies have found that Luminal B and HR+ subtypes offer better survival benefits. In the HER2-negative group, Luminal B demonstrated the most favorable prognosis, with an 8-year DFS of 69% (95% CI&#8201;=&#8201;64%&#8211;73%), compared to 62% (95% CI&#8201;=&#8201;54%&#8211;69%) for Luminal A and 63% (95% CI&#8201;=&#8201;60%&#8211;66%) for TNBC, respectively.<sup>
<xref rid="bibr23-17588359251321904" ref-type="bibr">23</xref>
</sup> Another study showed that HR+ patients have a better prognosis than HR&#8211;, in terms of OS, recurrence, or progression time. HR+ patients 8-year DFS rate was 65.80% (95% CI&#8201;=&#8201;63.40%&#8211;68.20%), compared to 63.40% (95% CI&#8201;=&#8201;61.20%&#8211;65.60%) for HR&#8211; patients. The 8-year OS rate was 88.10% (95% CI&#8201;=&#8201;86.30%&#8211;89.70%) for HR+ patients, while for HR&#8211; patients, it was 87.10% (95% CI&#8201;=&#8201;85.50%&#8211;88.50%).<sup>
<xref rid="bibr40-17588359251321904" ref-type="bibr">40</xref>
</sup> In a global multicenter retrospective study that evaluated the 8-year OS, BCSS, and PFS across different molecular subtypes, the 8-year DFS rates were as follows: Luminal A: 60.80% (95% CI&#8201;=&#8201;55.70%&#8211;65.40%), Luminal B: 69.7% (95% CI&#8201;=&#8201;66.20%&#8211;72.80%), TNBC: 63.5% (95% CI&#8201;=&#8201;61.10%&#8211;65.70%), and HER2+: 65.50% (95% CI&#8201;=&#8201;59.10%&#8211;71.10%). In addition, the 8-year OS rates were as follows: Luminal A at 87.80% (95% CI&#8201;=&#8201;83.90%&#8211;90.80%), Luminal B at 90.10% (95% CI&#8201;=&#8201;87.70%&#8211;92.00%), TNBC at 87% (95% CI&#8201;=&#8201;85.40%&#8211;88.50%), and HER2+ at 87.20% (95% CI&#8201;=&#8201;82.10%&#8211;90.90%). These findings suggest that BCYW with the Luminal B subtype tend to have better prognoses, with similar outcomes observed among BRCA mutation carriers.<sup>
<xref rid="bibr40-17588359251321904" ref-type="bibr">40</xref>
</sup> The study indicated that shorter survival times in BCYW were linked to a higher risk of recurrence or progression. Among these patients, those with Luminal B or HR+ subtypes had better OS, PFS, and BCSS. In the long-term treatment of BCYW, it is crucial not only to actively manage the primary tumor but also to remain vigilant about the impact of SPC on subsequent survival.</p></sec><sec id="section6-17588359251321904"><title>Survival time of SPC</title><p>Chinese research data show that the incidence of SPC in BCYW is 2.20% at 5&#8201;years and 4.40% at 10&#8201;years.<sup>
<xref rid="bibr38-17588359251321904" ref-type="bibr">38</xref>
</sup> There was a notable difference in OS between patients with and without SPC (10&#8201;years: 85.77% with SPC vs 86.37% without; 15&#8201;years: 66.16% vs 74.39%; 20&#8201;years: 49.21% vs 74.39%). Patients with a SPC had much worse long-term survival compared to those without.<sup>
<xref rid="bibr55-17588359251321904" ref-type="bibr">55</xref>
</sup> In addition, the survival time of patients with a SPC varies in different regions. In a small sample study of 163 cases in Shanghai, China, it was found that the 5-year, 10-year, and 15-year OS rates of BCYW with an SPC were 88.34%, 64.42%, and 56.44%, respectively.<sup>
<xref rid="bibr52-17588359251321904" ref-type="bibr">52</xref>
</sup> Similarly, in a study of 53,783 BCYW in Taiwan, 1-year, 5-year, 10-year, and 15-year survival rates for patients with a SPC were 71%, 40%, 30%, and 23%, respectively.<sup>
<xref rid="bibr50-17588359251321904" ref-type="bibr">50</xref>
</sup> By contrast, in a Korean study of 52,506 women with BC, the 5-year OS rate for BCYW with an SPC was significantly higher than in Taiwan, China, at 62.28% (95% CI&#8201;=&#8201;65.53&#8211;69.02).<sup>
<xref rid="bibr52-17588359251321904" ref-type="bibr">52</xref>
</sup> In patients with SPC, the 5-year OS is highest for thyroid cancer (5-year OS&#8201;=&#8201;89.6%), followed by cervical cancer (5-year OS&#8201;=&#8201;75.3%) and colorectal cancer (5-year OS&#8201;=&#8201;73.9%). However, the lowest 5-year OS among second primary cancers is observed in lung cancer (5-year OS&#8201;=&#8201;21.5%).<sup>
<xref rid="bibr70-17588359251321904" ref-type="bibr">70</xref>
</sup> Although survival time after developing an SPC in BCYW varies by region, long-term survival outcomes are generally poor. This makes SPC the second leading cause of death for BCYW, after the primary cancer itself.</p></sec></sec><sec id="section7-17588359251321904"><title>Genetic susceptibility implies the risk of BCYW and SPC</title><p>BRCA1/2 PVs are the most common individual mutations in familial breast cancer, increasing the risk of developing BC by 3&#8211;5 times.<sup>
<xref rid="bibr71-17588359251321904" ref-type="bibr">71</xref>
</sup> BCYW &lt;50&#8201;years tend to be more aggressive and advanced, often linked to inherited PVs, such as those in the BRCA gene.<sup><xref rid="bibr59-17588359251321904" ref-type="bibr">59</xref>,<xref rid="bibr69-17588359251321904" ref-type="bibr">69</xref></sup> One study found that approximately 12% of BCYW &lt; 40&#8201;years of age are associated with germline PVs in the BC susceptibility genes BRCA1/2.<sup><xref rid="bibr41-17588359251321904" ref-type="bibr">41</xref>,<xref rid="bibr72-17588359251321904" ref-type="bibr">72</xref></sup> Even in another study, very young BC (age&#8201;&#10877;&#8201;35) were found to have a 9.4% chance of having a detectable BRCA1/2 PVs.<sup><xref rid="bibr42-17588359251321904" ref-type="bibr">42</xref>,<xref rid="bibr73-17588359251321904" ref-type="bibr">73</xref></sup> Compared to older women (&#10878;&#8201;40&#8201;years), HR+ HER2&#8722; early BC in younger women shows distinct genomic characteristics. These include a higher frequency of GATA3 PVs (19% vs 16%) and copy number amplifications (47% vs 26%), but a lower frequency of PIK3CA (32% vs 47%), CDH1 (3% vs 9%), and MAP3K1 (7% vs 12%) PVs. However, most BC carry pathogenic mutations in only one gene, and the co-occurrence of germline PVs in both BRCA1 and BRCA2 is rare.<sup>
<xref rid="bibr39-17588359251321904" ref-type="bibr">39</xref>
</sup></p><p>Similarly, studies on SPBC are more common in carriers of BRCA1 or BRCA2 PVs.<sup>
<xref rid="bibr41-17588359251321904" ref-type="bibr">41</xref>
</sup> Several studies have shown that BRCA1 PV carriers have a cumulative risk of CBC of 15% at 5&#8201;years, rising to 27% at 10&#8201;years. In BRCA2 PV carriers, the cumulative risk of CBC is 9% at 5&#8201;years, increasing to 19% at 10&#8201;years. The 5-year cumulative risk of developing an SPC is approximately five times higher in women with BRCA1 mutations and three times higher in those with BRCA2 PVs compared to non-carriers. Moreover, Peking University Cancer Hospital conducted a study on the 10-year cumulative risk of CBC in BC patients with BRCA PVs. The 10-year cumulative CBC risk was 15.5% (95% CI&#8201;=&#8201;9.99&#8211;24.20) for BRCA1 PVs carriers, 17.5% (95% CI&#8201;=&#8201;10.90&#8211;28.00) for BRCA2 carriers, and 3.20% (95% CI&#8201;=&#8201;2.50&#8211;4.10) for non-carriers. In addition, BRCA1 PV carriers first diagnosed with BC at or before age 40 had a significantly higher 10-year cumulative risk of CBC (21.50% vs 11.90%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.044).<sup>
<xref rid="bibr59-17588359251321904" ref-type="bibr">59</xref>
</sup> Similarly, a recent 10-year study in the United States found that the 5-year risk of SPBC in germline PV carriers was 5.50% (95% CI 1.60%&#8211;19.60%), and the 10-year risk was 8.90% (95% CI&#8201;=&#8201;2.60%&#8211;30.30%). These rates were significantly higher compared to non-carriers, whose 5-year risk was 1.30% (95% CI&#8201;=&#8201;0.70%&#8211;2.60%) and 10-year risk was 2.20% (95% CI&#8201;=&#8201;1.20%&#8211;4.00%).<sup>
<xref rid="bibr61-17588359251321904" ref-type="bibr">61</xref>
</sup> Thus, approximately 12% of BCYW cases are linked to germline PVs in BRCA1 or BRCA2. Moreover, the cumulative risk of developing a SPC increases almost exponentially every 5&#8201;years.</p></sec><sec id="section8-17588359251321904"><title>Therapy associated with BCYW and SPC</title><sec id="section9-17588359251321904"><title>Surgery and SPC risk</title><p>BC treatment options include surgery, radiotherapy (RT), chemotherapy (CT), endocrine therapy (ET), and targeted therapy. Younger patients or those with large, aggressive tumors are more likely to undergo mastectomy and contralateral risk reduction surgery (CRRS).<sup><xref rid="bibr74-17588359251321904" ref-type="bibr">74</xref>,<xref rid="bibr75-17588359251321904" ref-type="bibr">75</xref></sup> A U.S. study found a rapid increase in the rate of CRRS, rising from 10% in 2004 to 33% in 2012 among women aged 20&#8211;44, and from 4% to 10% in women aged 45 and older during the same period. This indicates that younger women with BC are increasingly opting for mastectomy combined with CRRS to reduce the risk of future recurrence.<sup>
<xref rid="bibr44-17588359251321904" ref-type="bibr">44</xref>
</sup> A Korean study found that surgery for PBC at age&#8201;&#10877;&#8201;35 (hazard ratios, HR&#8201;=&#8201;2.49) doubled the risk of developing CBC.<sup>
<xref rid="bibr54-17588359251321904" ref-type="bibr">54</xref>
</sup> Ten years after BC surgery, the incidence of an SPC was 0.93% in the CRRS group, compared to 4.44% in the unilateral mastectomy (UM) group, with bilateral Mastectomy (BM) reducing the risk by approximately 78.50%. After 15&#8201;years, the incidence increased to 1.15% in CRRS patients and 7.77% in UM patients.<sup>
<xref rid="bibr61-17588359251321904" ref-type="bibr">61</xref>
</sup> While BM reduces the risk of recurrence and SPC, patients still face a certain level of risk. Within the first 10&#8201;years, this approach provides better outcomes compared to UM, benefiting both the primary cancer and SPC. However, after 15&#8201;years, the risk of developing a SPC following BM becomes more pronounced.</p></sec><sec id="section10-17588359251321904"><title>Endocrine therapy and SPC risk</title><p>Furthermore, elevated estrogen levels in women can also result in the abnormal proliferation of breast ducts, which may ultimately lead to BC.<sup>
<xref rid="bibr76-17588359251321904" ref-type="bibr">76</xref>
</sup> Therefore, approximately 70% of patients with HR+ BC can achieve antitumor effects by reducing estrogen levels through ET.<sup><xref rid="bibr77-17588359251321904" ref-type="bibr">77</xref>,<xref rid="bibr78-17588359251321904" ref-type="bibr">78</xref></sup> Similarly, a 2023 EBCTCG meta-analysis further confirmed that OFS or ovarian ablation significantly reduced the 15-year recurrence risk, breast cancer-specific mortality, and overall mortality.<sup>
<xref rid="bibr45-17588359251321904" ref-type="bibr">45</xref>
</sup> In patients aged&#8201;&#10877;&#8201;35&#8201;years, the combination of aromatase inhibitors and OFS resulted in better 12-year DFS and it may also provide an OS benefit.<sup>
<xref rid="bibr79-17588359251321904" ref-type="bibr">79</xref>
</sup> However, multiple studies have indicated that the use of AIs in postmenopausal BC patients may not sufficiently suppress estradiol and estrone levels.<sup><xref rid="bibr80-17588359251321904" ref-type="bibr">80</xref>,<xref rid="bibr81-17588359251321904" ref-type="bibr">81</xref></sup> Consequently, this inadequacy can lead to an increased risk of SPBC events, particularly among tamoxifen-treated patients with a history of uterine cancer.<sup>
<xref rid="bibr82-17588359251321904" ref-type="bibr">82</xref>
</sup> A study in the UK showed that women with BC with HT (SIR&#8201;=&#8201;2.30, 95% CI&#8201;=&#8201;2.21&#8211;2.40) had a higher SIR than those without HT (SIR&#8201;=&#8201;1.95, 95% CI&#8201;=&#8201;1.86&#8211;2.04). In the era of widespread use of ET, the incidence of second primary endometrial cancer in BC patients receiving HT has significantly increased.<sup>
<xref rid="bibr56-17588359251321904" ref-type="bibr">56</xref>
</sup> ET has varying effects depending on the site of action. Studies have demonstrated that the incidence of CBC in patients treated with tamoxifen for 5&#8201;years progressively decreases over a 30-year follow-up period. Patients who received tamoxifen for 5&#8201;years experienced an increased incidence of endometrial cancer. Conversely, the incidence of lung cancer, especially small-cell and squamous-cell lung cancers, was reduced in this treatment group.<sup>
<xref rid="bibr83-17588359251321904" ref-type="bibr">83</xref>
</sup> Indeed, ET has a dual effect on patients with early-stage BC. On one hand, it can inhibit estrogen resistance in PBC, and on the other hand, it helps reduce the risk of an SPBC, providing a protective role against secondary tumors.<sup>
<xref rid="bibr84-17588359251321904" ref-type="bibr">84</xref>
</sup></p></sec><sec id="section11-17588359251321904"><title>Radiotherapy and SPC risk</title><p>RT has the potential to lead to the development of SPC through ionizing radiation. Therefore, it is considered a risk factor for tumor occurrence and progression. Survivors with RT have a higher risk of developing SPC (SHR&#8201;=&#8201;1.161, 95% CI&#8201;=&#8201;1.109&#8211;1.217, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). By contrast, patients only with CT have a slightly reduced risk of developing SPC (SHR&#8201;=&#8201;0.880, 95% CI&#8201;=&#8201;0.832&#8211;0.931, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).<sup>
<xref rid="bibr62-17588359251321904" ref-type="bibr">62</xref>
</sup> However, when chest RT is added to CT, the adverse effects of radiation gradually appear. In addition to the risk of leukemia and myelodysplastic syndromes,<sup><xref rid="bibr85-17588359251321904" ref-type="bibr">85</xref>,<xref rid="bibr86-17588359251321904" ref-type="bibr">86</xref></sup> the risk of developing SPC in irradiated areas is significantly increased.<sup><xref rid="bibr52-17588359251321904" ref-type="bibr">52</xref>,<xref rid="bibr87-17588359251321904" ref-type="bibr">87</xref></sup> Studies show that RT patients have an elevated risk of any SPC, with specific risks for LC (SHR&#8201;=&#8201;1.109; 95% CI&#8201;=&#8201;1.033&#8211;1.192; <italic toggle="yes">p</italic>&#8201;=&#8201;0.045), BC (SHR&#8201;=&#8201;1.389; 95% CI&#8201;=&#8201;1.34&#8211;1.44; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and acute myeloid leukemia (SHR&#8201;=&#8201;1.298; 95% CI&#8201;=&#8201;1.01&#8211;1.67; <italic toggle="yes">p</italic>&#8201;=&#8201;0.045), particularly for LC, esophageal cancer, and CBC.<sup><xref rid="bibr63-17588359251321904" ref-type="bibr">63</xref><xref rid="bibr64-17588359251321904" ref-type="bibr"/>&#8211;<xref rid="bibr65-17588359251321904" ref-type="bibr">65</xref></sup> According to a study conducted in the United States, the CI of NBC SPC &gt;25&#8201;years is higher in the RT group compared to the non-RT group for patients of all ages.<sup>
<xref rid="bibr88-17588359251321904" ref-type="bibr">88</xref>
</sup> Patients with rare missense mutations in the ATM gene receive RT and have a higher risk of CBC. Specifically, the 10-year cumulative risk of CBC in these patients is 16% (95% CI&#8201;=&#8201;7.00%&#8211;36.50%). By contrast, similar patients not receiving RT have a 10-year cumulative risk of only 2.20% (95% CI&#8201;=&#8201;0.50%&#8211;9.00%). This indicates that the risk of CBC increases by approximately seven times for patients carrying rare missense mutations in ATM after receiving RT.<sup>
<xref rid="bibr67-17588359251321904" ref-type="bibr">67</xref>
</sup> The use of RT can indeed lead to the development of SPC. RT kills tumor cells by inducing DNA damage. However, it also harms normal tissues and leads to the development of SPC.</p></sec><sec id="section12-17588359251321904"><title>Chemotherapy and SPC risk</title><p>In studies related to CT for BC, the results are inconsistent, and there is currently no definitive conclusion. Research indicates that patients undergoing CT experience a diminished likelihood of developing SPC. Specifically, the risk of LC is reduced (SHR&#8201;=&#8201;0.895; 95% CI&#8201;=&#8201;0.818&#8211;0.979; <italic toggle="yes">p</italic>&#8201;=&#8201;0.015), and the risk of BC is also lowered (SHR&#8201;=&#8201;0.891; 95% CI&#8201;=&#8201;0.854&#8211;0.930; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Nonetheless, some studies have reported that the use of CT drugs can damage DNA, leading to an increased incidence of SPC.<sup>
<xref rid="bibr68-17588359251321904" ref-type="bibr">68</xref>
</sup> A study on young women with BC in the UK found differences in the (SIRs for myeloid leukemia related to CT: for those who received CT, the SIR&#8201;=&#8201;2.71 (95% CI&#8201;=&#8201;2.36&#8211;3.08), while for those who did not receive CT, the SIR&#8201;=&#8201;1.32 (95% CI&#8201;=&#8201;1.20&#8211;1.44).<sup>
<xref rid="bibr56-17588359251321904" ref-type="bibr">56</xref>
</sup> Surprisingly, two other studies showed different results. CT was significantly associated with a reduced BCSS in patients with ER deficiency (HR&#8201;=&#8201;0.51, 95% CI&#8201;=&#8201;0.29&#8211;0.90, <italic toggle="yes">p</italic>&#8201;=&#8201;0.020) or PR deficiency (HR&#8201;=&#8201;0.47, 95% CI&#8201;=&#8201;0.28&#8211;0.79, <italic toggle="yes">p</italic>&#8201;=&#8201;0.004).<sup>
<xref rid="bibr89-17588359251321904" ref-type="bibr">89</xref>
</sup> In addition, the use of adjuvant CT and ET was associated with a lower risk of CBC.<sup>
<xref rid="bibr90-17588359251321904" ref-type="bibr">90</xref>
</sup></p><p>In summary, questions remain regarding the therapy increase the risk of SPC. BC patients developing SPC after treatment may have a poorer prognosis than those with only BC. As a result, these patients may be unable to tolerate treatment for secondary tumors, and their options for medication are very limited, significantly reducing the effectiveness of treatment for SPC. Future studies in this area need to be strengthened to explore potential risk factors and effective treatment strategies in depth.<sup>
<xref rid="bibr70-17588359251321904" ref-type="bibr">70</xref>
</sup> Based on the above research findings, clinical physicians should take a comprehensive approach when making treatment decisions.</p></sec></sec><sec id="section13-17588359251321904"><title>Physiological and reproductive risk factors</title><p>The diagnosis of BCYW can be comprehensively analyzed and considered from physiological, reproductive, and psychosocial perspectives. Recent studies indicate that a short duration or lack of breastfeeding (BF), as well as abruptly stopping BF, can increase the risk of BC in young women.<sup>
<xref rid="bibr91-17588359251321904" ref-type="bibr">91</xref>
</sup> The occurrence of BC is closely related to advanced maternal age at first childbirth. Multiple studies have shown that having a first pregnancy at age 35 or older increases the risk of BC.<sup><xref rid="bibr92-17588359251321904" ref-type="bibr">92</xref>,<xref rid="bibr93-17588359251321904" ref-type="bibr">93</xref></sup> Similarly, the postpartum period is a high-risk window with an increased likelihood of developing new cancers and rapidly progressing subclinical metastatic phenotypes.<sup>
<xref rid="bibr94-17588359251321904" ref-type="bibr">94</xref>
</sup> Postpartum breast cancer (PPBC) patients often have a poorer survival prognosis. In a study, the overall mortality risk increased by 1.7 times in the PPBC group with a duration of 5 to less than 10&#8201;years (HR&#8201;=&#8201;1.72, 95% CI&#8201;=&#8201;1.17&#8211;2.52, <italic toggle="yes">p</italic>&#8201;=&#8201;0.006).<sup>
<xref rid="bibr95-17588359251321904" ref-type="bibr">95</xref>
</sup> In summary, giving birth for the first time after the age of 35, having interrupted or short BF, and being within 10&#8201;years postpartum are all associated with the risk of developing a SPC.</p><p>In addition, the occurrence of BC is influenced by various factors, including its physiological structure, hormonal changes, unhealthy lifestyle habits, and social psychological stress. The earlier the onset of menstruation, the higher the lifetime risk of BC, increasing by 5% for each year earlier. Similarly, each year, the menopause is delayed, the risk of BC rises by 2.8%&#8211;3.5%.<sup>
<xref rid="bibr96-17588359251321904" ref-type="bibr">96</xref>
</sup> Being overweight or obese, consuming alcohol, having lower fertility rates, experiencing irregular menstruation, and having high social-psychological stress can also contribute to the occurrence and development of BC.<sup><xref rid="bibr97-17588359251321904" ref-type="bibr">97</xref>,<xref rid="bibr98-17588359251321904" ref-type="bibr">98</xref></sup> A study on menstrual cycle irregularity found that women aged 29&#8211;46 with irregular menstruation have an 11% higher overall cancer risk than those with regular cycles.<sup>
<xref rid="bibr99-17588359251321904" ref-type="bibr">99</xref>
</sup> As mentioned above, factors such as late age at first pregnancy, short or sudden interruption of BF, early age at menarche, late menopause, a high-risk period postpartum (5&#8211;10&#8201;years), obesity, alcohol consumption, lower fertility rates, irregular menstruation, and increased social psychological stress contribute to a higher incidence of BCYW. Through the research outlined above, young women can implement control measures or interventions to reduce the risk of developing BC.</p></sec><sec id="section14-17588359251321904"><title>Summary and outlook</title><p>It is becoming increasingly clear that there is a complex relationship between BCYW and SPC. This study provides a comprehensive analysis of the epidemiology, molecular subtypes, genetic mutations, survival times, treatment methods, and reproductive factors related to both conditions. This article provides the relationship between BCYW and SPC, offering valuable insights for personalized treatment plans, risk assessment, and long-term follow-up in clinical practice.</p><p>The occurrence of SPC in BCYW remains a significant global health challenge for women. Despite advances in medical technology, the trend of increasing incidence of BC in younger populations continues to elevate the risk of developing SPC. There are still many gaps in research regarding this issue. To better identify BCYW and avoid late-stage diagnoses due to delayed detection, women &lt;40&#8201;years should be included in a comprehensive screening and treatment program (<xref rid="fig2-17588359251321904" ref-type="fig">Figure 2</xref>). Young women should be aware of whether any direct relatives have a history of BC. They should also conduct self-examinations of both breasts for any lumps, nodules, skin changes resembling orange peel, or nipple discharge and retraction. In addition, young women should complete BC screenings regularly and on schedule. For those with a family history of BC, it is advisable to undergo genetic testing to determine whether they carry PVs in the BRCA1/2 genes. If young BC is diagnosed, the patient&#8217;s prognosis and the risk of SPC should be estimated based on the molecular subtype of the BC and the type of PVs. Clinicians should explain the benefits and risks of treatment to patients. For surgical options, it is important to be vigilant about the risk of SPC occurring 10&#8211;15&#8201;years later. For HR+ patients, it is essential to closely monitor and actively prevent the development of endometrial cancer while undergoing ET. RT carries a high risk for the occurrence of SPC in the chest, and patients should be fully informed about the dual nature of these treatments. Young women can also take relevant intervention measures to reduce the occurrence of high-risk factors. For example, it is advisable to have the first pregnancy between the ages of 25 and 30. In addition, maintaining regular menstrual cycles and a healthy body weight, providing self-encouragement and stress reduction, and avoiding harmful habits such as smoking and drinking are all important steps.</p><p>Of course, the above represents an ideal situation, and many current studies still cannot fully explain the underlying mechanisms. First, the mechanisms leading to precancerous and tumor phenotypes are still unclear, and the changes in cancer tissue or the surrounding stromal components remain unknown. This makes it difficult to identify causal signals and their targets. For example, what causes the development of the TNBC, and whether pathogenic genetic mutations have corresponding therapeutic targets. Second, the field of BCYW still lacks strong predictive biomarkers and risk assessment screening tools. Factors related to BC, such as age, hormone levels, menstrual cycles, menopausal status, pregnancy, number of pregnancies, and BF, need to be evaluated as potential independent predictors of SPC in young BC survivors. Therefore, more predictive models are needed for further validation. Third, to better understand the risk of SPC in BCYW and the potential cellular basis, it is essential to describe the details of the hormonal interactions and feedback regulation between the breast and its stroma, as well as the hypothalamic&#8211;pituitary&#8211;gonadal axis. In addition, we need to explore how these signals affect breast development and the occurrence of SPC during cyclical reproduction. Thus, a comprehensive understanding and research into the occurrence of SPC in BCYW is necessary and aligns with current research trends.</p><p>In summary, this review emphasizes the occurrence of SPC, particularly among young BC survivors. Consequently, regular monitoring and screening, along with appropriate treatment plans that weigh the benefits and risks, are crucial for BC survivors to enable early detection and intervention of potential SPC.</p></sec></body><back><ack><p>None.</p></ack><fn-group><fn fn-type="other"><p><bold>ORCID iDs:</bold> Xinyi Liang <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_17588359251321904-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0004-6610-1207" ext-link-type="uri">https://orcid.org/0009-0004-6610-1207</ext-link></p><p>Yiwei Qin <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_17588359251321904-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0001-1871-4699" ext-link-type="uri">https://orcid.org/0009-0001-1871-4699</ext-link></p><p>Pengwei Li <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_17588359251321904-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0003-4037-8569" ext-link-type="uri">https://orcid.org/0009-0003-4037-8569</ext-link></p><p>You Mo <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_17588359251321904-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-5283-0741" ext-link-type="uri">https://orcid.org/0000-0001-5283-0741</ext-link></p><p>Dawei Chen <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_17588359251321904-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-6762-7997" ext-link-type="uri">https://orcid.org/0000-0002-6762-7997</ext-link></p></fn></fn-group><sec id="section15-17588359251321904"><title>Declarations</title><fn-group><fn fn-type="other"><p><bold>Ethics approval and consent to participate:</bold> This article does not contain any studies with human or animal participants. Consent to participate: not applicable.</p></fn><fn fn-type="other"><p><bold>Consent for publication:</bold> Not applicable.</p></fn><fn fn-type="con"><p><bold>Author contributions:</bold>
<bold>Xinyi Liang:</bold> Data curation; Formal analysis; Investigation; Writing &#8211; original draft; Writing &#8211; review &amp; editing.</p><p><bold>Yiwei Qin:</bold> Investigation; Writing &#8211; review &amp; editing.</p><p><bold>Pengwei Li:</bold> Investigation; Writing &#8211; review &amp; editing.</p><p><bold>You Mo:</bold> Conceptualization; Formal analysis; Supervision; Writing &#8211; review &amp; editing.</p><p><bold>Dawei Chen:</bold> Conceptualization; Funding acquisition; Project administration; Supervision; Validation; Writing &#8211; review &amp; editing.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> This work was funded by the National Natural Science Foundation of China (82172676, 82373217), the Natural Science Foundation of Shandong (ZR2024JQ032), Shandong Natural Science Foundation Major Basic Research Project (ZR2023ZD26), Project supported by the State Key Program of National Natural Science of China (82030082).</p></fn><fn fn-type="COI-statement"><p>The authors declare that there is no conflict of interest.</p></fn><fn fn-type="other"><p><bold>Availability of data and materials:</bold> No datasets were generated or analyzed during the current study. Further inquiries can be directed to the corresponding author.</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bibr1-17588359251321904"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name></person-group>, <etal>et al</etal>. <article-title>Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source><year>2021</year>; <volume>71</volume>: <fpage>209</fpage>&#8211;<lpage>249</lpage>.<pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></mixed-citation></ref><ref id="bibr2-17588359251321904"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodmer</surname><given-names>A</given-names></name><name name-style="western"><surname>Feller</surname><given-names>A</given-names></name><name name-style="western"><surname>Bordoni</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <article-title>Breast cancer in younger women in Switzerland 1996-2009: a longitudinal population-based study</article-title>. <source>Breast</source><year>2015</year>; <volume>24</volume>: <fpage>112</fpage>&#8211;<lpage>117</lpage>.<pub-id pub-id-type="pmid">25522906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.breast.2014.11.004</pub-id></mixed-citation></ref><ref id="bibr3-17588359251321904"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merlo</surname><given-names>DF</given-names></name><name name-style="western"><surname>Ceppi</surname><given-names>M</given-names></name><name name-style="western"><surname>Filiberti</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>. <article-title>Breast cancer incidence trends in European women aged 20&#8211;39 years at diagnosis</article-title>. <source>Breast Cancer Res Treat</source><year>2012</year>; <volume>134</volume>: <fpage>363</fpage>&#8211;<lpage>370</lpage>.<pub-id pub-id-type="pmid">22456983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-012-2031-7</pub-id></mixed-citation></ref><ref id="bibr4-17588359251321904"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molina-Montes</surname><given-names>E</given-names></name><name name-style="western"><surname>Requena</surname><given-names>M</given-names></name><name name-style="western"><surname>S&#225;nchez-Cantalejo</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>. <article-title>Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis</article-title>. <source>Gynecol Oncol</source><year>2015</year>; <volume>136</volume>: <fpage>158</fpage>&#8211;<lpage>171</lpage>.<pub-id pub-id-type="pmid">25448459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2014.10.029</pub-id></mixed-citation></ref><ref id="bibr5-17588359251321904"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>M</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>ME</given-names></name><name name-style="western"><surname>Rumgay</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>. <article-title>Current and future burden of breast cancer: global statistics for 2020 and 2040</article-title>. <source>Breast</source><year>2022</year>; <volume>66</volume>: <fpage>15</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">36084384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.breast.2022.08.010</pub-id><pub-id pub-id-type="pmcid">PMC9465273</pub-id></mixed-citation></ref><ref id="bibr6-17588359251321904"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>RA</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name></person-group>, <etal>et al</etal>. <article-title>Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status</article-title>. <source>Cancer</source><year>2021</year>; <volume>127</volume>: <fpage>3310</fpage>&#8211;<lpage>3324</lpage>.<pub-id pub-id-type="pmid">34002851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.33602</pub-id></mixed-citation></ref><ref id="bibr7-17588359251321904"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Copson</surname><given-names>E</given-names></name><name name-style="western"><surname>Eccles</surname><given-names>B</given-names></name><name name-style="western"><surname>Maishman</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>. <article-title>Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study</article-title>. <source>J Natl Cancer Inst</source><year>2013</year>; <volume>105</volume>: <fpage>978</fpage>&#8211;<lpage>988</lpage>.<pub-id pub-id-type="pmid">23723422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djt134</pub-id></mixed-citation></ref><ref id="bibr8-17588359251321904"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeo</surname><given-names>W</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HM</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <article-title>Risk factors and natural history of breast cancer in younger Chinese women</article-title>. <source>World J Clin Oncol</source><year>2014</year>; <volume>5</volume>: <fpage>1097</fpage>&#8211;<lpage>1106</lpage>.<pub-id pub-id-type="pmid">25493246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5306/wjco.v5.i5.1097</pub-id><pub-id pub-id-type="pmcid">PMC4259937</pub-id></mixed-citation></ref><ref id="bibr9-17588359251321904"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raymond</surname><given-names>JS</given-names></name><name name-style="western"><surname>Hogue</surname><given-names>CJR</given-names></name></person-group>. <article-title>Multiple primary tumours in women following breast cancer, 1973&#8211;2000</article-title>. <source>Br J Cancer</source><year>2006</year>; <volume>94</volume>: <fpage>1745</fpage>&#8211;<lpage>1750</lpage>.<pub-id pub-id-type="pmid">16721370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjc.6603172</pub-id><pub-id pub-id-type="pmcid">PMC2361329</pub-id></mixed-citation></ref><ref id="bibr10-17588359251321904"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ricceri</surname><given-names>F</given-names></name><name name-style="western"><surname>Fasanelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Giraudo</surname><given-names>MT</given-names></name></person-group>, <etal>et al</etal>. <article-title>Risk of second primary malignancies in women with breast cancer: results from the European prospective investigation into cancer and nutrition (EPIC)</article-title>. <source>Int J Cancer</source><year>2015</year>; <volume>137</volume>: <fpage>940</fpage>&#8211;<lpage>948</lpage>.<pub-id pub-id-type="pmid">25650288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.29462</pub-id></mixed-citation></ref><ref id="bibr11-17588359251321904"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>PS</given-names></name><name name-style="western"><surname>Barker</surname><given-names>KA</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>WF</given-names></name></person-group>. <article-title>Estrogen receptor status and the future burden of invasive and in situ breast cancers in the United States</article-title>. <source>J Natl Cancer Inst</source><year>2015</year>; <volume>107</volume>: <fpage>20150610</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djv159</pub-id><pub-id pub-id-type="pmcid">PMC4836802</pub-id><pub-id pub-id-type="pmid">26063794</pub-id></mixed-citation></ref><ref id="bibr12-17588359251321904"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Louwman</surname><given-names>WJ</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>. <article-title>Primary malignancy after primary female breast cancer in the South of the Netherlands, 1972-2001</article-title>. <source>Breast Cancer Res Treat</source><year>2005</year>; <volume>93</volume>: <fpage>91</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">16184464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-005-4016-2</pub-id></mixed-citation></ref><ref id="bibr13-17588359251321904"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>GP</given-names></name><name name-style="western"><surname>Schantz</surname><given-names>SP</given-names></name><name name-style="western"><surname>Neugut</surname><given-names>AI</given-names></name></person-group>, <etal>et al</etal>. <article-title>Incidences and trends of second cancers in female breast cancer patients: a fixed inception cohort-based analysis (United States)</article-title>. <source>Cancer Causes Control</source><year>2006</year>; <volume>17</volume>: <fpage>411</fpage>&#8211;<lpage>420</lpage>.<pub-id pub-id-type="pmid">16596293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10552-005-0338-y</pub-id></mixed-citation></ref><ref id="bibr14-17588359251321904"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name><name name-style="western"><surname>Nogueira</surname><given-names>L</given-names></name><name name-style="western"><surname>Mariotto</surname><given-names>AB</given-names></name></person-group>, <etal>et al</etal>. <article-title>Cancer treatment and survivorship statistics, 2019</article-title>. <source>CA Cancer J Clin</source><year>2019</year>; <volume>69</volume>: <fpage>363</fpage>&#8211;<lpage>385</lpage>.<pub-id pub-id-type="pmid">31184787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21565</pub-id></mixed-citation></ref><ref id="bibr15-17588359251321904"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corso</surname><given-names>G</given-names></name><name name-style="western"><surname>Veronesi</surname><given-names>P</given-names></name><name name-style="western"><surname>Santomauro</surname><given-names>GI</given-names></name></person-group>, <etal>et al</etal>. <article-title>Multiple primary non-breast tumors in breast cancer survivors</article-title>. <source>J Cancer Res Clin Oncol</source><year>2018</year>; <volume>144</volume>: <fpage>979</fpage>&#8211;<lpage>986</lpage>.<pub-id pub-id-type="pmid">29502170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00432-018-2621-9</pub-id><pub-id pub-id-type="pmcid">PMC11813444</pub-id></mixed-citation></ref><ref id="bibr16-17588359251321904"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <article-title>Risk of Second primary female genital malignancies in women with breast cancer: a SEER analysis</article-title>. <source>Horm Cancer</source><year>2018</year>; <volume>9</volume>: <fpage>197</fpage>&#8211;<lpage>204</lpage>.<pub-id pub-id-type="pmid">29556910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12672-018-0330-0</pub-id><pub-id pub-id-type="pmcid">PMC5945714</pub-id></mixed-citation></ref><ref id="bibr17-17588359251321904"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graber-Naidich</surname><given-names>A</given-names></name><name name-style="western"><surname>Choi</surname><given-names>E</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JT</given-names></name></person-group>, <etal>et al</etal>. <article-title>Smoking and the risk of second primary lung cancer among breast cancer survivors from the population-based UK biobank study</article-title>. <source>Clin Lung Cancer</source><year>2024</year>; <volume>25</volume>: 705&#8211;711.e7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cllc.2024.08.017</pub-id><pub-id pub-id-type="pmid">39332922</pub-id></mixed-citation></ref><ref id="bibr18-17588359251321904"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Park</surname><given-names>SL</given-names></name><name name-style="western"><surname>Wilkens</surname><given-names>LR</given-names></name></person-group>, <etal>et al</etal>. <article-title>Genetic risk of second primary cancer in breast cancer survivors: the multiethnic cohort study</article-title>. <source>Cancer Res</source><year>2022</year>; <volume>82</volume>(<issue>18</issue>): <fpage>3201</fpage>&#8211;<lpage>3208</lpage>.<pub-id pub-id-type="pmid">35834270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-21-4461</pub-id><pub-id pub-id-type="pmcid">PMC9481694</pub-id></mixed-citation></ref><ref id="bibr19-17588359251321904"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schonfeld</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Morton</surname><given-names>LM</given-names></name><name name-style="western"><surname>Berrington</surname><given-names>de</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <article-title>Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000-2015</article-title>. <source>Cancer Epidemiology</source><year>2020</year>; <volume>64</volume>: <fpage>101664</fpage>.<pub-id pub-id-type="pmid">31884334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canep.2019.101664</pub-id><pub-id pub-id-type="pmcid">PMC7096211</pub-id></mixed-citation></ref><ref id="bibr20-17588359251321904"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name><name name-style="western"><surname>Nogueira</surname><given-names>L</given-names></name><name name-style="western"><surname>Devasia</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>. <article-title>Cancer treatment and survivorship statistics, 2022</article-title>. <source>CA Cancer J Clin</source><year>2022</year>; <volume>72</volume>: <fpage>409</fpage>&#8211;<lpage>436</lpage>.<pub-id pub-id-type="pmid">35736631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21731</pub-id></mixed-citation></ref><ref id="bibr21-17588359251321904"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name></person-group>. <article-title>Second malignancies after breast cancer: the impact of adjuvant therapy</article-title>. <source>Mol Clin Oncol</source><year>2014</year>; <volume>2</volume>: <fpage>331</fpage>&#8211;<lpage>336</lpage>.<pub-id pub-id-type="pmid">24772296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mco.2014.250</pub-id><pub-id pub-id-type="pmcid">PMC3999127</pub-id></mixed-citation></ref><ref id="bibr22-17588359251321904"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>S</given-names></name><name name-style="western"><surname>Boddicker</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Na</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <article-title>Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2</article-title>. <source>J Clin Oncol</source><year>2023</year>; <volume>41</volume>: <fpage>1703</fpage>&#8211;<lpage>1713</lpage>.<pub-id pub-id-type="pmid">36623243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.22.01239</pub-id><pub-id pub-id-type="pmcid">PMC10022863</pub-id></mixed-citation></ref><ref id="bibr23-17588359251321904"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Chu</surname><given-names>F</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <article-title>BRCA-CRisk: a contralateral breast cancer risk prediction model for BRCA carriers</article-title>. <source>J Clin Oncol</source><year>2023</year>; <volume>41</volume>: <fpage>991</fpage>&#8211;<lpage>999</lpage>.<pub-id pub-id-type="pmid">36480783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.22.00833</pub-id></mixed-citation></ref><ref id="bibr24-17588359251321904"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellington</surname><given-names>TD</given-names></name><name name-style="western"><surname>Miller</surname><given-names>JW</given-names></name><name name-style="western"><surname>Henley</surname><given-names>SJ</given-names></name></person-group>, <etal>et al</etal>. <article-title>Trends in breast cancer incidence, by race, ethnicity, and age among women aged &#10878;20 years &#8211; United States, 1999-2018</article-title>. <source>MMWR Morb Mortal Wkly Rep</source><year>2022</year>; <volume>71</volume>(<issue>2</issue>): <fpage>43</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">35025856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7102a2</pub-id><pub-id pub-id-type="pmcid">PMC8757618</pub-id></mixed-citation></ref><ref id="bibr25-17588359251321904"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardoso</surname><given-names>F</given-names></name><name name-style="western"><surname>Kyriakides</surname><given-names>S</given-names></name><name name-style="western"><surname>Ohno</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source><year>2019</year>; <volume>30</volume>(<issue>8</issue>): <fpage>1194</fpage>&#8211;<lpage>1220</lpage>.<pub-id pub-id-type="pmid">31161190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdz173</pub-id></mixed-citation></ref><ref id="bibr26-17588359251321904"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paluch-Shimon</surname><given-names>S</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>F</given-names></name><name name-style="western"><surname>Partridge</surname><given-names>AH</given-names></name></person-group>, <etal>et al</etal>. <article-title>ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)</article-title>. <source>Ann Oncol</source><year>2022</year>; <volume>33</volume>: <fpage>1097</fpage>&#8211;<lpage>1118</lpage>.<pub-id pub-id-type="pmid">35934170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2022.07.007</pub-id></mixed-citation></ref><ref id="bibr27-17588359251321904"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeSantis</surname><given-names>CE</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name></person-group>. <article-title>Trends in stage at diagnosis for young breast cancer patients in the United States</article-title>. <source>Breast Cancer Res Treat</source><year>2019</year>; <volume>173</volume>: <fpage>743</fpage>&#8211;<lpage>747</lpage>.<pub-id pub-id-type="pmid">30426307</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-018-5042-1</pub-id></mixed-citation></ref><ref id="bibr28-17588359251321904"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xia</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>. <article-title>Landscape of young breast cancer under 35 years in China over the past decades: a multicentre retrospective cohort study (YBCC-Catts study)</article-title>. <source>EClinicalMedicine</source><year>2023</year>; <volume>64</volume>: <fpage>102243</fpage>.<pub-id pub-id-type="pmid">37936654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.102243</pub-id><pub-id pub-id-type="pmcid">PMC10626170</pub-id></mixed-citation></ref><ref id="bibr29-17588359251321904"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassaine</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jacquet</surname><given-names>E</given-names></name><name name-style="western"><surname>Seigneurin</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <article-title>Evolution of breast cancer incidence in young women in a French registry from 1990 to 2018: Towards a change in screening strategy?</article-title><source>Breast Cancer Res</source><year>2022</year>; <volume>24</volume>: <fpage>87</fpage>.<pub-id pub-id-type="pmid">36471434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13058-022-01581-5</pub-id><pub-id pub-id-type="pmcid">PMC9724405</pub-id></mixed-citation></ref><ref id="bibr30-17588359251321904"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fazel</surname><given-names>A</given-names></name><name name-style="western"><surname>Hasanpour-Heidari</surname><given-names>S</given-names></name><name name-style="western"><surname>Salamat</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal>. <article-title>Marked increase in breast cancer incidence in young women: a 10-year study from Northern Iran, 2004-2013</article-title>. <source>Cancer Epidemiol</source><year>2019</year>; <volume>62</volume>: <fpage>101573</fpage>.<pub-id pub-id-type="pmid">31330422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canep.2019.101573</pub-id></mixed-citation></ref><ref id="bibr31-17588359251321904"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadjadi</surname><given-names>A</given-names></name><name name-style="western"><surname>Nouraie</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghorbani</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <article-title>Epidemiology of breast cancer in the Islamic Republic of Iran: first results from a population-based cancer registry</article-title>. <source>East Mediterr Health J</source><year>2009</year>; <volume>15</volume>: <fpage>1426</fpage>&#8211;<lpage>1431</lpage>.<pub-id pub-id-type="pmid">20218134</pub-id></mixed-citation></ref><ref id="bibr32-17588359251321904"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joko-Fru</surname><given-names>WY</given-names></name><name name-style="western"><surname>Jedy-Agba</surname><given-names>E</given-names></name><name name-style="western"><surname>Korir</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <article-title>The evolving epidemic of breast cancer in sub-Saharan Africa: results from the African Cancer Registry Network</article-title>. <source>Int J Cancer</source><year>2020</year>; <volume>147</volume>: <fpage>2131</fpage>&#8211;<lpage>2141</lpage>.<pub-id pub-id-type="pmid">32306390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.33014</pub-id></mixed-citation></ref><ref id="bibr33-17588359251321904"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spronk</surname><given-names>I</given-names></name><name name-style="western"><surname>Schellevis</surname><given-names>FG</given-names></name><name name-style="western"><surname>Burgers</surname><given-names>JS</given-names></name></person-group>, <etal>et al</etal>. <article-title>Incidence of isolated local breast cancer recurrence and contralateral breast cancer: a systematic review</article-title>. <source>Breast</source><year>2018</year>; <volume>39</volume>: <fpage>70</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">29621695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.breast.2018.03.011</pub-id></mixed-citation></ref><ref id="bibr34-17588359251321904"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Chang</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Chang</surname><given-names>YJ</given-names></name></person-group>. <article-title>Treatment and long-term outcome of breast cancer in very young women: nationwide population-based study</article-title>. <source>BJS Open</source><year>2021</year>; <fpage>5</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bjsopen/zrab087</pub-id><pub-id pub-id-type="pmcid">PMC8529521</pub-id><pub-id pub-id-type="pmid">34672342</pub-id></mixed-citation></ref><ref id="bibr35-17588359251321904"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvarez-Ba&#241;uelos</surname><given-names>MT</given-names></name><name name-style="western"><surname>Segura-Jaramillo</surname><given-names>KA</given-names></name><name name-style="western"><surname>G&#243;mez-Rivera</surname><given-names>EdC</given-names></name></person-group>, <etal>et al</etal>. <article-title>Age under 30 years as a predictor of poor survival in a cohort of Mexican women with breast cancer</article-title>. <source>Cancer Control</source><year>2021</year>; <volume>28</volume>: <fpage>10732748211047408</fpage>.<pub-id pub-id-type="pmid">34670417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/10732748211047408</pub-id><pub-id pub-id-type="pmcid">PMC8546434</pub-id></mixed-citation></ref><ref id="bibr36-17588359251321904"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaffar</surname><given-names>R</given-names></name><name name-style="western"><surname>Bouchardy</surname><given-names>C</given-names></name><name name-style="western"><surname>Chappuis</surname><given-names>PO</given-names></name></person-group>, <etal>et al</etal>. <article-title>A population-based cohort of young women diagnosed with breast cancer in Geneva, Switzerland</article-title>. <source>PLoS One</source><year>2019</year>; <volume>14</volume>: e0222136. 20190906.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0222136</pub-id><pub-id pub-id-type="pmcid">PMC6730928</pub-id><pub-id pub-id-type="pmid">31491032</pub-id></mixed-citation></ref><ref id="bibr37-17588359251321904"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>. <article-title>The disparities in prognostic prediction and annualized hazard function in different molecular subtypes between young Chinese and White American women with breast cancer</article-title>. <source>Front Oncol</source><year>2023</year>; <volume>13</volume>: <volume>1199492</volume>. <fpage>20230710</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1199492</pub-id><pub-id pub-id-type="pmcid">PMC10364598</pub-id><pub-id pub-id-type="pmid">37492473</pub-id></mixed-citation></ref><ref id="bibr38-17588359251321904"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Billena</surname><given-names>C</given-names></name><name name-style="western"><surname>Wilgucki</surname><given-names>M</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <article-title>10-Year Breast Cancer Outcomes in Women &lt;/=35 years of age</article-title>. <source>Int J Radiat Oncol Biol Phys</source><year>2021</year>; <volume>109</volume>: <fpage>1007</fpage>&#8211;<lpage>1018</lpage>.<pub-id pub-id-type="pmid">33371964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijrobp.2020.10.022</pub-id><pub-id pub-id-type="pmcid">PMC8006530</pub-id></mixed-citation></ref><ref id="bibr39-17588359251321904"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schettini</surname><given-names>F</given-names></name><name name-style="western"><surname>Blondeaux</surname><given-names>E</given-names></name><name name-style="western"><surname>Molinelli</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>. <article-title>Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: results of a large international retrospective cohort study</article-title>. <source>Cancer</source><year>2024</year>; <volume>130</volume>: <fpage>2746</fpage>&#8211;<lpage>2762</lpage>.<pub-id pub-id-type="pmid">38752572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.35323</pub-id></mixed-citation></ref><ref id="bibr40-17588359251321904"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arecco</surname><given-names>L</given-names></name><name name-style="western"><surname>Bruzzone</surname><given-names>M</given-names></name><name name-style="western"><surname>Bas</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>. <article-title>Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers</article-title>. <source>Ann Oncol</source><year>2024</year>; <volume>35</volume>: <fpage>792</fpage>&#8211;<lpage>804</lpage>.<pub-id pub-id-type="pmid">38908482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2024.06.009</pub-id></mixed-citation></ref><ref id="bibr41-17588359251321904"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Copson</surname><given-names>ER</given-names></name><name name-style="western"><surname>Maishman</surname><given-names>TC</given-names></name><name name-style="western"><surname>Tapper</surname><given-names>WJ</given-names></name></person-group>, <etal>et al</etal>. <article-title>Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study</article-title>. <source>Lancet Oncol</source><year>2018</year>; <volume>19</volume>: <fpage>169</fpage>&#8211;<lpage>180</lpage>.<pub-id pub-id-type="pmid">29337092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(17)30891-4</pub-id><pub-id pub-id-type="pmcid">PMC5805863</pub-id></mixed-citation></ref><ref id="bibr42-17588359251321904"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malone</surname><given-names>KE</given-names></name><name name-style="western"><surname>Darling</surname><given-names>JR</given-names></name><name name-style="western"><surname>Neal</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>. <article-title>Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases</article-title>. <source>Cancer</source><year>2000</year>; <volume>88</volume>(<issue>6</issue>): <fpage>1393</fpage>&#8211;<lpage>1402</lpage>.<pub-id pub-id-type="pmid">10717622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(sici)1097-0142(20000315)88:6&lt;1393::aid-cncr17&gt;3.0.co;2-p</pub-id></mixed-citation></ref><ref id="bibr43-17588359251321904"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luen</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Viale</surname><given-names>G</given-names></name><name name-style="western"><surname>Nik-Zainal</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>Genomic characterisation of hormone receptor-positive breast cancer arising in very young women</article-title>. <source>Ann Oncol</source><year>2023</year>; <volume>34</volume>: <fpage>397</fpage>&#8211;<lpage>409</lpage>.<pub-id pub-id-type="pmid">36709040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2023.01.009</pub-id><pub-id pub-id-type="pmcid">PMC10619213</pub-id></mixed-citation></ref><ref id="bibr44-17588359251321904"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nash</surname><given-names>R</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>M</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CC</given-names></name></person-group>, <etal>et al</etal>. <article-title>State variation in the receipt of a contralateral prophylactic mastectomy among women who received a diagnosis of invasive unilateral early-stage breast cancer in the United States, 2004-2012</article-title>. <source>JAMA Surg</source><year>2017</year>; <volume>152</volume>: <fpage>648</fpage>&#8211;<lpage>657</lpage>.<pub-id pub-id-type="pmid">28355431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamasurg.2017.0115</pub-id><pub-id pub-id-type="pmcid">PMC5831458</pub-id></mixed-citation></ref><ref id="bibr45-17588359251321904"><label>45</label><mixed-citation publication-type="journal"><collab>Early Breast Cancer Trialists&#8217; Collaborative G</collab>. <article-title>Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials</article-title>. <source>Lancet</source><year>2005</year>; <volume>365</volume>: <fpage>1687</fpage>&#8211;<lpage>1717</lpage>.<pub-id pub-id-type="pmid">15894097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(05)66544-0</pub-id></mixed-citation></ref><ref id="bibr46-17588359251321904"><label>46</label><mixed-citation publication-type="journal"><collab>Early Breast Cancer Trialists&#8217; Collaborative G</collab>, <person-group person-group-type="author"><name name-style="western"><surname>Darby</surname><given-names>S</given-names></name><name name-style="western"><surname>McGale</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>. <article-title>Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials</article-title>. <source>Lancet</source><year>2011</year>; <volume>378</volume>: <fpage>1707</fpage>&#8211;<lpage>1716</lpage>.<pub-id pub-id-type="pmid">22019144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(11)61629-2</pub-id><pub-id pub-id-type="pmcid">PMC3254252</pub-id></mixed-citation></ref><ref id="bibr47-17588359251321904"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>TH</given-names></name><name name-style="western"><surname>El Helali</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>. <article-title>Trends and age, sex, and race disparities in time to second primary cancer from 1990 to 2019</article-title>. <source>Cancer Med</source><year>2023</year>; <volume>12</volume>: <fpage>22316</fpage>&#8211;<lpage>22324</lpage>.<pub-id pub-id-type="pmid">38063337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.6785</pub-id><pub-id pub-id-type="pmcid">PMC10757087</pub-id></mixed-citation></ref><ref id="bibr48-17588359251321904"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brandt</surname><given-names>C</given-names></name><name name-style="western"><surname>Vo</surname><given-names>JB</given-names></name><name name-style="western"><surname>Gierach</surname><given-names>GL</given-names></name></person-group>, <etal>et al</etal>. <article-title>Second primary cancer risks according to race and ethnicity among U.S. breast cancer survivors</article-title>. <source>Int J Cancer</source><year>2024</year>; <volume>155</volume>: <fpage>996</fpage>&#8211;<lpage>1006</lpage>.<pub-id pub-id-type="pmid">38685564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.34971</pub-id><pub-id pub-id-type="pmcid">PMC11250897</pub-id></mixed-citation></ref><ref id="bibr49-17588359251321904"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Degeneffe</surname><given-names>A</given-names></name><name name-style="western"><surname>De Maertelaer</surname><given-names>V</given-names></name><name name-style="western"><surname>De Witte</surname><given-names>O</given-names></name></person-group>, <etal>et al</etal>. <article-title>The association between meningioma and breast cancer</article-title>. <source>JAMA Network Open</source><year>2023</year>; <volume>6</volume>: e2318620.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.18620</pub-id><pub-id pub-id-type="pmcid">PMC10276307</pub-id><pub-id pub-id-type="pmid">37326990</pub-id></mixed-citation></ref><ref id="bibr50-17588359251321904"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>KD</given-names></name><name name-style="western"><surname>Chen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chan</surname><given-names>CH</given-names></name></person-group>, <etal>et al</etal>. <article-title>Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source><year>2008</year>; <volume>17</volume>: <fpage>2647</fpage>&#8211;<lpage>2655</lpage>.<pub-id pub-id-type="pmid">18843006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-08-0109</pub-id></mixed-citation></ref><ref id="bibr51-17588359251321904"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goncalves</surname><given-names>E</given-names></name><name name-style="western"><surname>Fontes</surname><given-names>F</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>JR</given-names></name></person-group>, <etal>et al</etal>. <article-title>Second primary cancers among females with a first primary breast cancer: a population-based study in Northern Portugal</article-title>. <source>Breast Cancer Res Treat</source><year>2024</year>; <volume>204</volume>: <fpage>367</fpage>&#8211;<lpage>376</lpage>.<pub-id pub-id-type="pmid">38151690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-023-07224-3</pub-id></mixed-citation></ref><ref id="bibr52-17588359251321904"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name></person-group>, <etal>et al</etal>. <article-title>Epidemiology of second non-breast primary cancers among survivors of breast cancer: a Korean population-based study by the SMARTSHIP Group</article-title>. <source>Cancer Res Treat</source><year>2023</year>; <volume>55</volume>: <fpage>580</fpage>&#8211;<lpage>591</lpage>.<pub-id pub-id-type="pmid">36596730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4143/crt.2022.410</pub-id><pub-id pub-id-type="pmcid">PMC10101780</pub-id></mixed-citation></ref><ref id="bibr53-17588359251321904"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>BX</given-names></name><name name-style="western"><surname>Brantley</surname><given-names>KD</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>SM</given-names></name></person-group>, <etal>et al</etal>. <article-title>Second primary non-breast cancers in young breast cancer survivors</article-title>. <source>Breast Cancer Res Treat</source><year>2024</year>; <volume>207</volume>: <fpage>587</fpage>&#8211;<lpage>597</lpage>.<pub-id pub-id-type="pmid">38858235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-024-07400-z</pub-id></mixed-citation></ref><ref id="bibr54-17588359251321904"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>TI</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>Age-related incidence and peak occurrence of contralateral breast cancer</article-title>. <source>JAMA Netw Open</source><year>2023</year>; <volume>6</volume>: e2347511.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.47511</pub-id><pub-id pub-id-type="pmcid">PMC10724757</pub-id><pub-id pub-id-type="pmid">38100108</pub-id></mixed-citation></ref><ref id="bibr55-17588359251321904"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Weng</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>. <article-title>Risk of second primary cancers among long-term survivors of breast cancer</article-title>. <source>Front Oncol</source><year>2019</year>; <volume>9</volume>: <fpage>1426</fpage>.<pub-id pub-id-type="pmid">31998630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2019.01426</pub-id><pub-id pub-id-type="pmcid">PMC6970432</pub-id></mixed-citation></ref><ref id="bibr56-17588359251321904"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>I</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>H</given-names></name><name name-style="western"><surname>Joko-Fru</surname><given-names>WY</given-names></name></person-group>, <etal>et al</etal>. <article-title>Risks of second primary cancers among 584,965 female and male breast cancer survivors in England: a 25-year retrospective cohort study</article-title>. <source>Lancet Reg Health Eur</source><year>2024</year>; <volume>40</volume>: <fpage>100903</fpage>.<pub-id pub-id-type="pmid">38745989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lanepe.2024.100903</pub-id><pub-id pub-id-type="pmcid">PMC11092881</pub-id></mixed-citation></ref><ref id="bibr57-17588359251321904"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>. <article-title>Predictive models for overall survival in breast cancer patients with a second primary malignancy: a real-world study in Shanghai, China</article-title>. <source>BMC Womens Health</source><year>2022</year>; <volume>22</volume>: <fpage>498</fpage>.<pub-id pub-id-type="pmid">36474253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12905-022-02079-0</pub-id><pub-id pub-id-type="pmcid">PMC9724326</pub-id></mixed-citation></ref><ref id="bibr58-17588359251321904"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molina-Montes</surname><given-names>E</given-names></name><name name-style="western"><surname>Perez-Nevot</surname><given-names>B</given-names></name><name name-style="western"><surname>Pollan</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: a systematic review and meta-analysis</article-title>. <source>Breast</source><year>2014</year>; <volume>23</volume>: <fpage>721</fpage>&#8211;<lpage>742</lpage>.<pub-id pub-id-type="pmid">25467311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.breast.2014.10.005</pub-id></mixed-citation></ref><ref id="bibr59-17588359251321904"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>. <article-title>Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients</article-title>. <source>Int J Cancer</source><year>2020</year>; <volume>146</volume>: <fpage>3335</fpage>&#8211;<lpage>3342</lpage>.<pub-id pub-id-type="pmid">32037537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.32918</pub-id></mixed-citation></ref><ref id="bibr60-17588359251321904"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brantley</surname><given-names>KD</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>SM</given-names></name><name name-style="western"><surname>Collins</surname><given-names>LC</given-names></name></person-group>, <etal>et al</etal>. <article-title>Second primary breast cancer in young breast cancer survivors</article-title>. <source>JAMA Oncol</source><year>2024</year>; <volume>10</volume>: <fpage>718</fpage>&#8211;<lpage>725</lpage>.<pub-id pub-id-type="pmid">38602683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2024.0286</pub-id><pub-id pub-id-type="pmcid">PMC11009864</pub-id></mixed-citation></ref><ref id="bibr61-17588359251321904"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>S</given-names></name><name name-style="western"><surname>Pappas</surname><given-names>L</given-names></name><name name-style="western"><surname>Matsen</surname><given-names>CB</given-names></name></person-group>, <etal>et al</etal>. <article-title>Second primary breast cancer after unilateral mastectomy alone or with contralateral prophylactic mastectomy</article-title>. <source>Cancer Med</source><year>2020</year>; <volume>9</volume>: <fpage>8043</fpage>&#8211;<lpage>8052</lpage>.<pub-id pub-id-type="pmid">32918537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.3394</pub-id><pub-id pub-id-type="pmcid">PMC7643660</pub-id></mixed-citation></ref><ref id="bibr62-17588359251321904"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watt</surname><given-names>GP</given-names></name><name name-style="western"><surname>John</surname><given-names>EM</given-names></name><name name-style="western"><surname>Bandera</surname><given-names>EV</given-names></name></person-group>, <etal>et al</etal>. <article-title>Race, ethnicity and risk of second primary contralateral breast cancer in the United States</article-title>. <source>Int J Cancer</source><year>2021</year>; <volume>148</volume>: <fpage>2748</fpage>&#8211;<lpage>2758</lpage>.<pub-id pub-id-type="pmid">33544892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.33501</pub-id><pub-id pub-id-type="pmcid">PMC9059169</pub-id></mixed-citation></ref><ref id="bibr63-17588359251321904"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burt</surname><given-names>LM</given-names></name><name name-style="western"><surname>Ying</surname><given-names>J</given-names></name><name name-style="western"><surname>Poppe</surname><given-names>MM</given-names></name></person-group>, <etal>et al</etal>. <article-title>Risk of secondary malignancies after radiation therapy for breast cancer: Comprehensive results</article-title>. <source>Breast</source><year>2017</year>; <volume>35</volume>: <fpage>122</fpage>&#8211;<lpage>129</lpage>.<pub-id pub-id-type="pmid">28719811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.breast.2017.07.004</pub-id></mixed-citation></ref><ref id="bibr64-17588359251321904"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berrington</surname><given-names>de</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>A</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>RE</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>. <article-title>Second solid cancers after radiotherapy for breast cancer in SEER cancer registries</article-title>. <source>Br J Cancer</source><year>2010</year>; <volume>102</volume>: <fpage>220</fpage>&#8211;<lpage>226</lpage>.<pub-id pub-id-type="pmid">19935795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjc.6605435</pub-id><pub-id pub-id-type="pmcid">PMC2813734</pub-id></mixed-citation></ref><ref id="bibr65-17588359251321904"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morton</surname><given-names>LM</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>ES</given-names></name><name name-style="western"><surname>Hall</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>. <article-title>Risk of treatment-related esophageal cancer among breast cancer survivors</article-title>. <source>Ann Oncol</source><year>2012</year>; <volume>23</volume>: <fpage>3081</fpage>&#8211;<lpage>3091</lpage>.<pub-id pub-id-type="pmid">22745217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mds144</pub-id><pub-id pub-id-type="pmcid">PMC3501231</pub-id></mixed-citation></ref><ref id="bibr66-17588359251321904"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaapveld</surname><given-names>M</given-names></name><name name-style="western"><surname>Visser</surname><given-names>O</given-names></name><name name-style="western"><surname>Louwman</surname><given-names>MJ</given-names></name></person-group>, <etal>et al</etal>. <article-title>Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study</article-title>. <source>J Clin Oncol</source><year>2008</year>; <volume>26</volume>: <fpage>1239</fpage>&#8211;<lpage>1246</lpage>.<pub-id pub-id-type="pmid">18323547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2007.11.9081</pub-id></mixed-citation></ref><ref id="bibr67-17588359251321904"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiner</surname><given-names>AS</given-names></name><name name-style="western"><surname>Robson</surname><given-names>ME</given-names></name><name name-style="western"><surname>Mellemkjaer</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>. <article-title>Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC pathogenic variants and risk of contralateral breast cancer</article-title>. <source>J Natl Cancer Inst</source><year>2020</year>; <volume>112</volume>: <fpage>1275</fpage>&#8211;<lpage>1279</lpage>.<pub-id pub-id-type="pmid">32119081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djaa031</pub-id><pub-id pub-id-type="pmcid">PMC7735763</pub-id></mixed-citation></ref><ref id="bibr68-17588359251321904"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>JL</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Shao</surname><given-names>ZM</given-names></name></person-group>. <article-title>Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study</article-title>. <source>Int J Clin Oncol</source><year>2019</year>; <volume>24</volume>: <fpage>934</fpage>&#8211;<lpage>940</lpage>.<pub-id pub-id-type="pmid">30888527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10147-019-01430-0</pub-id></mixed-citation></ref><ref id="bibr69-17588359251321904"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoemaker</surname><given-names>ML</given-names></name><name name-style="western"><surname>White</surname><given-names>MC</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013</article-title>. <source>Breast Cancer Res Treat</source><year>2018</year>; <volume>169</volume>: <fpage>595</fpage>&#8211;<lpage>606</lpage>.<pub-id pub-id-type="pmid">29445940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-018-4699-9</pub-id><pub-id pub-id-type="pmcid">PMC5955792</pub-id></mixed-citation></ref><ref id="bibr70-17588359251321904"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>. <article-title>Characteristics and survival analysis of breast cancer survivors with metachronous double primary cancers: a retrospective cohort study</article-title>. <source>Transl Cancer Res</source><year>2023</year>; <volume>12</volume>: <fpage>939</fpage>&#8211;<lpage>948</lpage>.<pub-id pub-id-type="pmid">37180649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tcr-23-301</pub-id><pub-id pub-id-type="pmcid">PMC10174759</pub-id></mixed-citation></ref><ref id="bibr71-17588359251321904"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name><name name-style="western"><surname>Fidler-Benaoudia</surname><given-names>M</given-names></name><name name-style="western"><surname>Keegan</surname><given-names>TH</given-names></name></person-group>, <etal>et al</etal>. <article-title>Cancer statistics for adolescents and young adults, 2020</article-title>. <source>CA Cancer J Clin</source><year>2020</year>; <volume>70</volume>: <fpage>443</fpage>&#8211;<lpage>459</lpage>.<pub-id pub-id-type="pmid">32940362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21637</pub-id></mixed-citation></ref><ref id="bibr72-17588359251321904"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guzman-Arocho</surname><given-names>YD</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>SM</given-names></name><name name-style="western"><surname>Garber</surname><given-names>JE</given-names></name></person-group>, <etal>et al</etal>. <article-title>Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer</article-title>. <source>Br J Cancer</source><year>2022</year>; <volume>126</volume>: <fpage>302</fpage>&#8211;<lpage>309</lpage>.<pub-id pub-id-type="pmid">34703009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-021-01597-2</pub-id><pub-id pub-id-type="pmcid">PMC8770707</pub-id></mixed-citation></ref><ref id="bibr73-17588359251321904"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azim</surname><given-names>HA</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Partridge</surname><given-names>A</given-names></name></person-group>. <article-title>Biology of breast cancer in young women</article-title>. <source>Breast Cancer Res</source><year>2014</year>; <volume>16</volume>(<issue>4</issue>): <fpage>427</fpage>.<pub-id pub-id-type="pmid">25436920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13058-014-0427-5</pub-id><pub-id pub-id-type="pmcid">PMC4303229</pub-id></mixed-citation></ref><ref id="bibr74-17588359251321904"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freedman</surname><given-names>RA</given-names></name><name name-style="western"><surname>Virgo</surname><given-names>KS</given-names></name><name name-style="western"><surname>Labadie</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <article-title>Receipt of locoregional therapy among young women with breast cancer</article-title>. <source>Breast Cancer Res Treat</source><year>2012</year>; <volume>135</volume>: <fpage>893</fpage>&#8211;<lpage>906</lpage>.<pub-id pub-id-type="pmid">22949130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-012-2156-8</pub-id></mixed-citation></ref><ref id="bibr75-17588359251321904"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominici</surname><given-names>L</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>. <article-title>Association of local therapy with quality-of-life outcomes in young women with breast cancer</article-title>. <source>JAMA Surgery</source><year>2021</year>; <fpage>156</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamasurg.2021.3758</pub-id><pub-id pub-id-type="pmcid">PMC8411359</pub-id><pub-id pub-id-type="pmid">34468718</pub-id></mixed-citation></ref><ref id="bibr76-17588359251321904"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tesch</surname><given-names>ME</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>SM</given-names></name></person-group>, <etal>et al</etal>. <article-title>Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy</article-title>. <source>NPJ Breast Cancer</source><year>2024</year>; <volume>10</volume>: <fpage>67</fpage>.<pub-id pub-id-type="pmid">39090124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41523-024-00680-0</pub-id><pub-id pub-id-type="pmcid">PMC11294545</pub-id></mixed-citation></ref><ref id="bibr77-17588359251321904"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baek</surname><given-names>SY</given-names></name><name name-style="western"><surname>Noh</surname><given-names>WC</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>SH</given-names></name></person-group>, <etal>et al</etal>. <article-title>Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA Trial</article-title>. <source>J Clin Oncol</source><year>2023</year>; <volume>41</volume>: <fpage>4864</fpage>&#8211;<lpage>4871</lpage>.<pub-id pub-id-type="pmid">37607321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.00557</pub-id></mixed-citation></ref><ref id="bibr78-17588359251321904"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JW</given-names></name><name name-style="western"><surname>Nam</surname><given-names>SJ</given-names></name></person-group>, <etal>et al</etal>. <article-title>Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase iii trial</article-title>. <source>J Clin Oncol</source><year>2020</year>; <volume>38</volume>: <fpage>434</fpage>&#8211;<lpage>443</lpage>.<pub-id pub-id-type="pmid">31518174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.19.00126</pub-id></mixed-citation></ref><ref id="bibr79-17588359251321904"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pagani</surname><given-names>O</given-names></name><name name-style="western"><surname>Walley</surname><given-names>BA</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>GF</given-names></name></person-group>, <etal>et al</etal>. <article-title>Adjuvant Exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials</article-title>. <source>J Clin Oncol</source><year>2023</year>; <volume>41</volume>: <fpage>1376</fpage>&#8211;<lpage>1382</lpage>.<pub-id pub-id-type="pmid">36521078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.22.01064</pub-id><pub-id pub-id-type="pmcid">PMC10419413</pub-id></mixed-citation></ref><ref id="bibr80-17588359251321904"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#248;nning</surname><given-names>PE</given-names></name></person-group>. <article-title>Aromatase inhibitors in breast cancer</article-title>. <source>Endocr Relat Cancer</source><year>2004</year>; <volume>11</volume>(<issue>2</issue>): <fpage>179</fpage>&#8211;<lpage>189</lpage>.<pub-id pub-id-type="pmid">15163297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1677/erc.0.0110179</pub-id></mixed-citation></ref><ref id="bibr81-17588359251321904"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ingle</surname><given-names>JN</given-names></name><name name-style="western"><surname>Cairns</surname><given-names>J</given-names></name><name name-style="western"><surname>Suman</surname><given-names>VJ</given-names></name></person-group>, <etal>et al</etal>. <article-title>Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor alpha</article-title>. <source>Clin Cancer Res</source><year>2020</year>; <volume>26</volume>: <fpage>2986</fpage>&#8211;<lpage>2996</lpage>.<pub-id pub-id-type="pmid">32098767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-19-3091</pub-id><pub-id pub-id-type="pmcid">PMC7299827</pub-id></mixed-citation></ref><ref id="bibr82-17588359251321904"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersson</surname><given-names>M</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>MB</given-names></name><name name-style="western"><surname>Engholm</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>. <article-title>Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001</article-title>. <source>Acta Oncol</source><year>2008</year>; <volume>47</volume>: <fpage>755</fpage>&#8211;<lpage>764</lpage>.<pub-id pub-id-type="pmid">18465345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/02841860801978921</pub-id></mixed-citation></ref><ref id="bibr83-17588359251321904"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nordenskj&#246;ld</surname><given-names>A</given-names></name><name name-style="western"><surname>Fohlin</surname><given-names>H</given-names></name><name name-style="western"><surname>Rosell</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <article-title>Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy</article-title>. <source>Breast</source><year>2023</year>; <volume>71</volume>: <fpage>63</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">37517154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.breast.2023.07.010</pub-id><pub-id pub-id-type="pmcid">PMC10400913</pub-id></mixed-citation></ref><ref id="bibr84-17588359251321904"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Prognostic value of lymph node ratio in non-small-cell lung cancer: a meta-analysis</article-title>. <source>Jpn J Clin Oncol</source><year>2020</year>; <volume>50</volume>: <fpage>44</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">31735973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jjco/hyz120</pub-id></mixed-citation></ref><ref id="bibr85-17588359251321904"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moebus</surname><given-names>V</given-names></name><name name-style="western"><surname>Jackisch</surname><given-names>C</given-names></name><name name-style="western"><surname>Lueck</surname><given-names>HJ</given-names></name></person-group>, <etal>et al</etal>. <article-title>Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study</article-title>. <source>J Clin Oncol</source><year>2010</year>; <volume>28</volume>: <fpage>2874</fpage>&#8211;<lpage>2880</lpage>.<pub-id pub-id-type="pmid">20458045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2009.24.7643</pub-id></mixed-citation></ref><ref id="bibr86-17588359251321904"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirova</surname><given-names>YM</given-names></name><name name-style="western"><surname>De Rycke</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gambotti</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>. <article-title>Second malignancies after breast cancer: the impact of different treatment modalities</article-title>. <source>Brit J Cancer</source><year>2008</year>; <volume>98</volume>: <fpage>870</fpage>&#8211;<lpage>874</lpage>.<pub-id pub-id-type="pmid">18268495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjc.6604241</pub-id><pub-id pub-id-type="pmcid">PMC2266852</pub-id></mixed-citation></ref><ref id="bibr87-17588359251321904"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>. <article-title>The impact of radiotherapy on the incidence of secondary malignancies: a pan-cancer study in the US SEER cancer registries</article-title>. <source>Curr Oncol</source><year>2021</year>; <volume>28</volume>: <fpage>301</fpage>&#8211;<lpage>316</lpage>.<pub-id pub-id-type="pmid">33435562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/curroncol28010035</pub-id><pub-id pub-id-type="pmcid">PMC7903277</pub-id></mixed-citation></ref><ref id="bibr88-17588359251321904"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Mao</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>. <article-title>Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis</article-title>. <source>Breast Cancer Res Treat</source><year>2015</year>; <volume>150</volume>: <fpage>439</fpage>&#8211;<lpage>445</lpage>.<pub-id pub-id-type="pmid">25764167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-015-3315-5</pub-id><pub-id pub-id-type="pmcid">PMC4695996</pub-id></mixed-citation></ref><ref id="bibr89-17588359251321904"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group>, <etal>et al</etal>. <article-title>The changes of subtype markers between first and second primary breast cancers</article-title>. <source>Cancer Med</source><year>2023</year>; <volume>12</volume>: <fpage>13649</fpage>&#8211;<lpage>13660</lpage>.<pub-id pub-id-type="pmid">37096879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.5979</pub-id><pub-id pub-id-type="pmcid">PMC10315743</pub-id></mixed-citation></ref><ref id="bibr90-17588359251321904"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kramer</surname><given-names>I</given-names></name><name name-style="western"><surname>Schaapveld</surname><given-names>M</given-names></name><name name-style="western"><surname>Oldenburg</surname><given-names>HSA</given-names></name></person-group>, <etal>et al</etal>. <article-title>The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype</article-title>. <source>J Natl Cancer Inst</source><year>2019</year>; <volume>111</volume>: <fpage>709</fpage>&#8211;<lpage>718</lpage>.<pub-id pub-id-type="pmid">30698719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djz010</pub-id></mixed-citation></ref><ref id="bibr91-17588359251321904"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walbaum</surname><given-names>B</given-names></name><name name-style="western"><surname>Garcia-Fructuoso</surname><given-names>I</given-names></name><name name-style="western"><surname>Martinez-Saez</surname><given-names>O</given-names></name></person-group>, <etal>et al</etal>. <article-title>Hormone receptor-positive early breast cancer in young women: a comprehensive review</article-title>. <source>Cancer Treat Rev</source><year>2024</year>; <volume>129</volume>: <fpage>102804</fpage>.<pub-id pub-id-type="pmid">39084152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctrv.2024.102804</pub-id></mixed-citation></ref><ref id="bibr92-17588359251321904"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyons</surname><given-names>TR</given-names></name><name name-style="western"><surname>Schedin</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Borges</surname><given-names>VF</given-names></name></person-group>. <article-title>Pregnancy and breast cancer: when they collide</article-title>. <source>J Mammary Gland Biol Neoplasia</source><year>2009</year>; <volume>14</volume>: <fpage>87</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">19381788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10911-009-9119-7</pub-id><pub-id pub-id-type="pmcid">PMC2693784</pub-id></mixed-citation></ref><ref id="bibr93-17588359251321904"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nichols</surname><given-names>HB</given-names></name><name name-style="western"><surname>Schoemaker</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <article-title>Breast cancer risk after recent childbirth: a pooled analysis of 15 prospective studies</article-title>. <source>Ann Intern Med</source><year>2019</year>; <volume>170</volume>: <fpage>22</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">30534999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M18-1323</pub-id><pub-id pub-id-type="pmcid">PMC6760671</pub-id></mixed-citation></ref><ref id="bibr94-17588359251321904"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>AY</given-names></name><name name-style="western"><surname>Ahearn</surname><given-names>TU</given-names></name><name name-style="western"><surname>Behrens</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>Distinct reproductive risk profiles for intrinsic-like breast cancer subtypes: pooled analysis of population-based studies</article-title>. <source>J Natl Cancer Inst</source><year>2022</year>; <volume>114</volume>: <fpage>1706</fpage>&#8211;<lpage>1719</lpage>.<pub-id pub-id-type="pmid">35723569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djac117</pub-id><pub-id pub-id-type="pmcid">PMC9949579</pub-id></mixed-citation></ref><ref id="bibr95-17588359251321904"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ye</surname><given-names>S</given-names></name><name name-style="western"><surname>Bernhardt</surname><given-names>SM</given-names></name></person-group>, <etal>et al</etal>. <article-title>Postpartum breast cancer and survival in women with germline BRCA pathogenic variants</article-title>. <source>JAMA Netw Open</source><year>2024</year>; <volume>7</volume>: e247421.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2024.7421</pub-id><pub-id pub-id-type="pmcid">PMC11031688</pub-id><pub-id pub-id-type="pmid">38639936</pub-id></mixed-citation></ref><ref id="bibr96-17588359251321904"><label>96</label><mixed-citation publication-type="journal"><collab>Collaborative Group on Hormonal Factors in Breast Cancer</collab>. <article-title>Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies</article-title>. <source>Lancet Oncol</source><year>2012</year>; <volume>13</volume>: <fpage>1141</fpage>&#8211;<lpage>1151</lpage>.<pub-id pub-id-type="pmid">23084519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(12)70425-4</pub-id><pub-id pub-id-type="pmcid">PMC3488186</pub-id></mixed-citation></ref><ref id="bibr97-17588359251321904"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Fu</surname><given-names>W</given-names></name></person-group>, <etal>et al</etal>. <article-title>How young is too young in breast cancer? Young breast cancer is not a unique biological subtype</article-title>. <source>Clin Breast Cancer</source><year>2018</year>; <volume>18</volume>: e25&#8211;e39.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clbc.2017.05.015</pub-id><pub-id pub-id-type="pmid">28802528</pub-id></mixed-citation></ref><ref id="bibr98-17588359251321904"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menen</surname><given-names>RS</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>KK</given-names></name></person-group>. <article-title>Considerations for the treatment of young patients with breast cancer</article-title>. <source>Breast J</source><year>2016</year>; <volume>22</volume>: <fpage>667</fpage>&#8211;<lpage>672</lpage>.<pub-id pub-id-type="pmid">27542172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/tbj.12644</pub-id></mixed-citation></ref><ref id="bibr99-17588359251321904"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YX</given-names></name><name name-style="western"><surname>Sandoval-Insausti</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>. <article-title>Menstrual cycle characteristics and incident cancer: a prospective cohort study</article-title>. <source>Hum Reprod</source><year>2022</year>; <volume>37</volume>: <fpage>341</fpage>&#8211;<lpage>351</lpage>.<pub-id pub-id-type="pmid">34893843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/humrep/deab251</pub-id><pub-id pub-id-type="pmcid">PMC8804333</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>